[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 259
1. Van Patten K, Parkash V, Jain D: Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. Mod Pathol; 2010 Jan;23(1):38-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 38 cases (peritoneal endometriosis (n=14), gastrointestinal endometriosis (n=21: 11 colon, 8 appendix, 2 small bowel), and 3 cases of endometrioid carcinoma arising in colonic endometriosis (n=3)) were included in the study.
  • All three cases of carcinoma arising in colonic endometriosis showed a total loss of N-cadherin in the tumor, but preserved E-cadherin and beta-catenin expression.
  • In these cases, areas of benign endometriotic glands near the tumor showed weak and focal N-cadherin expression that was gradually lost.


2. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH: Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology; 2010 Dec;139(6):2072-2082.e5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: CD166 (also called activated leukocyte cell adhesion molecule [ALCAM]) is a marker of colorectal cancer (CRC) stem cells; it is expressed by aggressive tumors.
  • Although the presence of CD166 at the tumor cell surface has been correlated with shortened survival, little is known about its function and expression in normal intestinal epithelia.
  • Human and mouse intestinal tumors were also analyzed.
  • CD166 was located in the cytoplasm and at the surface of cells within human CRC tumors.
  • CD166-positive cells were also detected in benign adenomas in mice; rare cells coexpressed CD166 and CD44 or epithelial-specific antigen.
  • CD166-positive cells appear at multiple stages of intestinal carcinoma progression, including benign and metastatic tumors.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Exp Med. 1995 Jun 1;181(6):2213-20 [7760007.001]
  • [Cites] Differentiation. 2003 Jan;71(1):28-41 [12558601.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):805-13 [9502422.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):655-63 [9556065.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):930-40 [15048703.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1160-4 [15509676.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Exp Cell Res. 1992 Nov;203(1):91-9 [1426054.001]
  • [Cites] J Biol Chem. 1993 Aug 25;268(24):18345-58 [8349710.001]
  • [Cites] J Neurobiol. 1994 Jul;25(7):831-45 [8089660.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1563-8 [7535342.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):765-77 [9566975.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55315-23 [15496415.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1515-25 [15769845.001]
  • [Cites] Oncology. 2005;68(4-6):462-70 [16024937.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):403-9 [16484444.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2637-45 [16650408.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):877-84 [16818742.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):BR263-73 [16865058.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Development. 2007 Apr;134(8):1491-7 [17344225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):137-45 [18157132.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):353-60 [18264089.001]
  • [Cites] Stem Cells. 2008 Mar;26(3):630-7 [18055444.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1726-33 [18347173.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):947-58 [18259194.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):48-53 [18356041.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):915-20 [18536716.001]
  • [Cites] BMC Gastroenterol. 2008;8:57 [19055726.001]
  • [Cites] Cell. 2009 Mar 6;136(5):903-12 [19269367.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):427-39 [19427292.001]
  • [Cites] Nature. 2009 May 14;459(7244):262-5 [19329995.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G590-600 [20185687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(3-4):I-XI, 193-383 [11394186.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2134-42 [11568000.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1549-63 [12070283.001]
  • [Cites] Prostate. 2003 Jan 1;54(1):34-43 [12481253.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2706-16 [9108388.001]
  • (PMID = 20826154.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118235; United States / NIDDK NIH HHS / DK / U01 DK085525-02; United States / NHLBI NIH HHS / HL / T32 HL007781; United States / NCI NIH HHS / CA / CA106195-06A1; United States / NCI NIH HHS / CA / CA118235-05; United States / NICHD NIH HHS / HD / T32 HD049309-05; United States / NCI NIH HHS / CA / CA106195; United States / NCI NIH HHS / CA / T32 CA106195; United States / NICHD NIH HHS / HD / HD049309; United States / NICHD NIH HHS / HD / T32 HD049309; United States / NCI NIH HHS / CA / T32 CA106195-06A1; United States / NHLBI NIH HHS / HL / T32 HL007781-14; United States / NIDDK NIH HHS / DK / R01 DK068326; United States / NCI NIH HHS / CA / CA118235; United States / NIDDK NIH HHS / DK / R01 DK068326-05; United States / NIDDK NIH HHS / DK / DK068326; United States / NIDDK NIH HHS / DK / DK085525-02; United States / NICHD NIH HHS / HD / HD049309-05; United States / NHLBI NIH HHS / HL / HL007781-14; United States / NHLBI NIH HHS / HL / HL007781; United States / NIDDK NIH HHS / DK / U01 DK085525; United States / NIDDK NIH HHS / DK / DK085525; United States / NIDDK NIH HHS / DK / DK068326-05; United States / NCI NIH HHS / CA / R01 CA118235-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins
  • [Other-IDs] NLM/ NIHMS234467; NLM/ PMC2997177
  •  go-up   go-down


3. Gold DV, Stein R, Burton J, Goldenberg DM: Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol; 2010;4(1):1-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.
  • For PanIN lesions there was greater expression of CD74 within higher grade, PanIN-3 lesions, whereas the colonic adenomas showed no such trend, but overall, a higher frequency and intensity of CD74 labeling than was observed within the colon carcinomas.
  • These findings are supportive of a role for CD74 in the development and maintenance of gastrointestinal neo-plasia, and provide a rationale for development of therapeutic agents that are able to block CD74 function, specifically within the tumor cell.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Humans. Immunohistochemistry. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 May;158(5):1639-51 [11337362.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1481-9 [15923369.001]
  • [Cites] Cancer Lett. 2001 Jul 10;168(1):87-91 [11368882.001]
  • [Cites] Scand J Immunol. 2001 Jul-Aug;54(1-2):39-44 [11439146.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1467-76 [12782713.001]
  • [Cites] Gene Ther. 2003 Aug;10(17):1512-8 [12900767.001]
  • [Cites] Cancer Immunol Immunother. 2003 Oct;52(10):592-8 [12827305.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5546-50 [15313888.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6606-11 [15475450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Dec;80(24):7395-9 [6324166.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4568-77 [2663143.001]
  • [Cites] Nature. 1990 Jun 14;345(6276):615-8 [2190094.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2391-6 [1527384.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2419-26 [16638847.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6794-801 [16709839.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4807-16 [16484589.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s [17875789.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2784-92 [18056708.001]
  • [Cites] Infect Immun. 2008 Jul;76(7):3233-40 [18474653.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2808-17 [19351768.001]
  • [Cites] Eur J Cancer. 2009 Jun;45(9):1654-63 [19269807.001]
  • [Cites] World J Gastroenterol. 2009 Jun 21;15(23):2855-61 [19533806.001]
  • [Cites] World J Gastroenterol. 2010 Jul 14;16(26):3258-66 [20614481.001]
  • [Cites] J Neurooncol. 2010 Nov;100(2):177-86 [20443131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8581-5 [8397411.001]
  • [Cites] Nature. 1994 Apr 7;368(6471):551-4 [8139689.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):64-71 [8540610.001]
  • [Cites] Biochem J. 1996 Nov 15;320 ( Pt 1):293-300 [8947500.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91 [9192661.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):32-6 [10431843.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3705-11 [15297317.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1254-61 [15477757.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):171-6 [15972644.001]
  • [Cites] Immunology. 1999 Oct;98(2):296-302 [10540230.001]
  • (PMID = 21228923.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096924
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class II; 0 / invariant chain
  • [Other-IDs] NLM/ PMC3016099
  • [Keywords] NOTNLM ; CD74 / colon carcinoma / gastric carcinoma / invariant chain / pancreatic carcinoma
  •  go-up   go-down


Advertisement
4. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, Ho SM: Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet; 2009 Jan;5(1):e1000334
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
  • Alpha-methylacyl-coenzyme A racemase (AMACR) regulates peroxisomal beta-oxidation of phytol-derived, branched-chain fatty acids from red meat and dairy products -- suspected risk factors for colon carcinoma (CCa).
  • AMACR was first found overexpressed in prostate cancer but not in benign glands and is now an established diagnostic marker for prostate cancer.
  • By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire colon adenoma-carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-16 in a newly identified CpG island within the core promoter of AMACR.
  • It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression and was absent in villous adenomas and all CCas expressing variable levels of AMACR.
  • Our findings identified key in vivo events and novel transcription factors responsible for AMACR regulation in CCas and suggested these AMACR deletions may have diagnostic/prognostic value for colon carcinogenesis.
  • [MeSH-major] Colon / enzymology. Colonic Neoplasms / genetics. CpG Islands / genetics. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Racemases and Epimerases / genetics
  • [MeSH-minor] Adenoma, Villous / genetics. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Base Sequence. Binding Sites. Cell Differentiation. Cell Line, Tumor. Humans. Molecular Sequence Data. Polymorphism, Genetic. Repressor Proteins / metabolism. Sequence Deletion / genetics. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15685-90 [10748193.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):438-44 [11893780.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] J Lipid Res. 2003 May;44(5):968-77 [12611910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):775-83 [12917210.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Cancer Detect Prev. 2003;27(6):422-6 [14642549.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):47-53 [14689581.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):787-93 [14982833.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Cell. 1980 Oct;21(3):653-68 [6985477.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Genome Res. 2007 Jun;17(6):807-17 [17567999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1487-97 [17680641.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2008 Jun;116(6):769-76 [18560533.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1763-77 [18836037.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1325-33 [1463014.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):881-5 [9175734.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4 [15710887.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):110-8 [15755877.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):252-5 [16082251.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1410-5 [16105129.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] Atherosclerosis. 2006 Sep;188(1):43-50 [16289551.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):850-6 [17442371.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2700-7 [17477519.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):175-80 [17525630.001]
  • (PMID = 19148275.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112532; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA062269; United States / NCI NIH HHS / CA / CA062269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / ZNF202 protein, human; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2613032
  •  go-up   go-down


5. Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL: Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg; 2006 Nov;244(5):792-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis that is necessary for wound healing and also promotes tumor growth.
  • It is anticipated that plasma levels would increase after major surgery and that such elevations may facilitate tumor growth.
  • METHODS: Colorectal resection for cancer (n = 139) or benign pathology (n = 48) and gastric bypass for morbid obesity (n = 40) were assessed.
  • RESULTS: The mean preoperative VEGF level of the cancer patients was significantly higher than baseline level of benign colon patients.
  • CONCLUSION: As a group colon cancer patients prior to surgery have significantly higher mean VEGF levels than patients without tumors.
  • [MeSH-major] Colectomy. Colonic Diseases / surgery. Gastric Bypass. Minimally Invasive Surgical Procedures. Obesity, Morbid / surgery. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1105-9 [11488797.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):417-23 [11875709.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):36-9 [11961601.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Transfusion. 1999 Oct;39(10):1078-83 [10532601.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):333-8 [10671682.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3147-52 [10955796.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1264-70 [11071473.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1162-9 [11984655.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L1133-42 [12376368.001]
  • [Cites] Gastric Cancer. 2002;5(3):137-41 [12378339.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):271-4 [12807238.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1187-95 [14513066.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] J Surg Res. 2003 Nov;115(1):113-20 [14572781.001]
  • [Cites] Cytokine. 2004 Jan 21;25(2):68-72 [14693162.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Aug;90(8):1245-50 [2811843.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):956-64 [9528841.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1279-85 [9607588.001]
  • [Cites] Clin Sci (Lond). 1998 Apr;94(4):395-404 [9640345.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Surgery. 1998 Sep;124(3):516-25 [9736904.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1419-24 [9769380.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Chest. 1998 Dec;114(6):1668-75 [9872204.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):477-81 [10215047.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4804-7 [10519388.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] Int J Obes (Lond). 2005 Nov;29(11):1308-14 [15953938.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [CommentIn] Ann Surg. 2007 Jul;246(1):160-1; author reply 161 [17592305.001]
  • (PMID = 17060773.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1856599
  •  go-up   go-down


6. Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM: Incidental PET/CT findings in the cancer patient: how should they be managed? Surgery; 2009 Aug;146(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 133 patients evaluated further, clinicians identified a second primary malignancy in 41 patients (31%), benign disease in 62 patients (47%), and metastatic disease from their known malignancy in 30 patients (23%).
  • The most common sites for a proven second primary malignancy were: lung (N = 10), breast (N = 7), and colon (N = 5).
  • In our data, approximately half of these findings were benign, a third were consistent with a second primary malignancy or a metastatic focus, and the remainder were never evaluated due to physician and patient decision.
  • Advanced primary tumors are unlikely to be impacted by a second primary tumor suggesting that this subset of patients will not benefit from further investigation.
  • The timing and route of investigation should be dictated by clinical judgment and the status of the primary tumor.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628085.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Kadiyska TK, Kaneva RP, Nedin DG, Alexandrova AB, Gegova AT, Lalchev SG, Christova T, Mitev VI, Horst J, Bogdanova N, Kremensky IM: Novel MLH1 frameshift mutation in an extended hereditary nonpolyposis colorectal cancer family. World J Gastroenterol; 2006 Dec 28;12(48):7848-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides the typical clinical features of the syndrome, we found a specific pathologic manifestation such as moderate to high differentiated adenocarcinomas of the colon.
  • One of the mutation carriers developed a benign giant cell soft tissue tumor.
  • The primary tumor localizations were frequently extracolonic and detailed yearly gastrointestinal and gynecological examinations have been proposed to the mutation carriers.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Bulgaria. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic. Genetic Counseling. Humans. Male. Microsatellite Instability. Middle Aged. MutS Homolog 2 Protein / genetics. Sequence Deletion / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fam Cancer. 2005;4(3):227-32 [16136382.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):396-404 [15655560.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):208-20 [16434208.001]
  • [Cites] CA Cancer J Clin. 2006 Jul-Aug;56(4):213-25 [16870997.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4285-92 [16908935.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):118-127 [11112663.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):20-7 [12112654.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):741-9 [12118112.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):837-40 [12378626.001]
  • [Cites] Fam Cancer. 2003;2(1):9-13 [14574162.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]
  • [Cites] Biochim Biophys Acta. 1999 May 31;1423(3):O1-O10 [10382540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Fam Cancer. 2005;4(3):233-7 [16136383.001]
  • (PMID = 17203532.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ PMC4087554
  •  go-up   go-down


9. Mason CK, McFarlane S, Johnston PG, Crowe P, Erwin PJ, Domostoj MM, Campbell FC, Manaviazar S, Hale KJ, El-Tanani M: Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther; 2008 Mar;7(3):548-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this regard, past comparative assaying of the two agents against a range of human tumor cell lines has revealed that typically (-)-agelastatin A is 1.5 to 16 times more potent than cisplatin at inhibiting cell growth, its effects being most pronounced against human bladder, skin, colon, and breast carcinomas.
  • Suppression of Tcf-4 by RNA interference (short interfering RNA) induced malignant/invasive transformation in parental benign Rama 37 cells; significantly, these events were reversed by treatment with (-)-agelastatin A.
  • [MeSH-major] Alkaloids / pharmacology. Cell Adhesion / drug effects. Neoplasm Invasiveness / prevention & control. Osteopontin / physiology. Oxazolidinones / pharmacology
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Humans. Neoplasm Metastasis / prevention & control. Promoter Regions, Genetic. RNA Interference

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347142.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Oxazolidinones; 0 / agelastatin A; 106441-73-0 / Osteopontin
  •  go-up   go-down


10. Patel AC, Kulkarni GS, Kulkarni SG: Textiloma in the leg. Indian J Orthop; 2007 Jul;41(3):237-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Textiloma is defined as a tumor formed due to retained gauze.
  • We removed the soft tissue mass enbloc thinking it to be a benign tumor.
  • Textiloma can present as tumoral forms and can mimic as a pseudo-tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139751.001).
  • [ISSN] 0019-5413
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2989125
  • [Keywords] NOTNLM ; Textiloma / foreign body / pseudotumor
  •  go-up   go-down


11. Benavides MA, Hagen KL, Fang W, Du P, Lin S, Moyer MP, Yang W, Bland KI, Grizzle WE, Bosland MC: Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells. Anticancer Res; 2010 Jun;30(6):1881-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells.
  • MATERIALS AND METHODS: MCF-7 (breast), LNCaP (prostate), and LS-174 (colon) cancer cells (wild-type p53), DU-145 (prostate) and SW480 (colon) cancer cells (mutated p53), and immortalized, non-tumorigenic MCF-10A (breast), BPH-1 (prostate), and NCM-460 (colon) epithelial cells were used.
  • LNCaP and MCF-7 cells were arrested at G(1), but DU-145 at S.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biotechnol. 2008 Jun;39(2):113-8 [18327554.001]
  • [Cites] Curr Pharm Des. 2009;15(6):675-81 [19199988.001]
  • [Cites] J Nutr Biochem. 2008 Apr;19(4):207-15 [17707628.001]
  • [Cites] Nucleic Acids Res. 2008 Feb;36(2):e11 [18178591.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):287-96 [17591973.001]
  • [Cites] Am J Surg. 2007 Feb;193(2):274-83 [17236862.001]
  • [Cites] Phytochemistry. 2006 Aug;67(15):1686-98 [16766004.001]
  • [Cites] Med Chem. 2005 May;1(3):227-37 [16787318.001]
  • [Cites] J Biol Chem. 1953 Sep;204(1):403-16 [13084611.001]
  • [Cites] J Biol Chem. 1951 Feb;188(2):723-8 [14824160.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:1-14 [9679538.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5193-8 [7693333.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):453-8 [8375929.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4859-65 [2503245.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1409-16 [4357757.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] J Anim Sci. 2002 Aug;80(8):2197-206 [12211390.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Apr 23;11(8):961-4 [11327600.001]
  • [Cites] Cell Mol Life Sci. 2001 Feb;58(2):244-58 [11289306.001]
  • [Cites] Curr Pharm Des. 2009;15(8):893-916 [19275653.001]
  • [Cites] Bioinformatics. 2008 Jul 1;24(13):1547-8 [18467348.001]
  • [Cites] Curr Protoc Protein Sci. 2001 May;Appendix 4:Appendix 4K [18429085.001]
  • (PMID = 20651330.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116195; United States / NCI NIH HHS / CA / R01CA116195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; AE28F7PNPL / Methionine
  • [Other-IDs] NLM/ NIHMS623504; NLM/ PMC4166481
  •  go-up   go-down


12. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • METHODS: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC).
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.
  • Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


13. Di Valentino M, Menafoglio A, Mazzucchelli L, Siclari F, Gallino A: Rapid-growing left intraventricular cardiac hemangioma. J Am Soc Echocardiogr; 2006 Jul;19(7):939.e5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62 years old man with Child B liver cirrhosis, prostate cancer and a recent colon carcinoma resection was referred to our cardiology department for trans-thoracic-echocardiography (TTE) in order to establish left ventricular function before starting chemotherapy.
  • At follow-up TTE showed growing of the intra-cardiac tumor up to 27 x 10 mm, corresponding to a size increase of 1 mm/month.
  • Among different pathologies a rapid growing benign tumor with a high risk of systemic embolisation or an endocardial blood cyst were retained as possible diagnoses.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825010.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Shantha Kumara HM, Grieco MJ, Yan X, Kalady MF, DiMaggio V, Kim DG, Hyman N, Feingold DL, Whelan RL: Minimally invasive colorectal resection for cancer is associated with a short-lived decrease in soluble Tie-2 receptor levels, which may transiently inhibit VEGF-mediated angiogenesis (via altered blood levels of free Ang-1 and Ang-2). Surg Endosc; 2010 Oct;24(10):2581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After minimally invasive colorectal resection (MICR), Ang-1 levels decrease and Ang-2 levels increase, which may stimulate angiogenesis in wounds and residual tumor foci.
  • METHODS: Blood samples were taken preoperatively (PreOp) and on postoperative days (POD) 1 and 3 from 50 cancer and 53 benign disease MICR patients.
  • RESULTS: PreOp plasma sTie-2 levels were significantly higher in the benign group (27.6 ± 10.2) than in the cancer group (22.9 ± 7.9).
  • A significant drop from PreOp occurred in sTie-2 levels in the cancer group on POD1 (20.0 ± 7.4) and POD3 (21.0 ± 6.6) and in the benign group on POD1 (24.8 ± 9.1).
  • The benign group's POD3 and the cancer group's POD7-13 sTie-2 levels were statistically similar to the PreOp levels while the benign group's POD7-13 level was significantly higher.
  • The benign group's early results were similar.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Aug;25(8):2769-70 [21487885.001]
  • [Cites] J Cell Sci. 2005 Feb 15;118(Pt 4):771-80 [15687104.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] J Am Coll Cardiol. 2004 Feb 4;43(3):423-8 [15013125.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):539-44 [11298622.001]
  • [Cites] Ann Surg. 1966 Sep;164(3):491-502 [5951515.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33(10):1169-76 [17512160.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):777-80 [7687189.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):973-7 [19474682.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Dec;27(12 ):2619-26 [17901375.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Br J Cancer. 1996 Jul;74(1):69-72 [8679461.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2072-8 [9329972.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2355-60 [15302795.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):755-64 [16114015.001]
  • [Cites] Eur J Clin Invest. 2003 Jul;33(7):529-35 [12814387.001]
  • [Cites] Surgery. 2004 Aug;136(2):205-9 [15300181.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Eur J Clin Invest. 2006 Feb;36(2):127-32 [16436095.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(8):2011-22 [19223473.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2353-7 [15330184.001]
  • [Cites] Angiogenesis. 2001;4(2):123-31 [11806244.001]
  • [Cites] Surgery. 2003 Sep;134(3):432-6 [14555930.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6571-7 [7987857.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):964-9 [15742397.001]
  • [Cites] J Intern Med. 2005 Oct;258(4):336-43 [16164572.001]
  • [Cites] Br J Surg. 1985 Oct;72(10):771-6 [2412626.001]
  • (PMID = 20354881.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


15. Pertia A, Nikoleishvili D, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A: Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol; 2007;39(2):381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of cyclin-dependent kinase inhibitors (CDKI) in benign and malignant urological diseases is a subject of intense ongoing investigation.
  • The goal of the current study was to analyze the expression of p27((Kip1))CDKI in benign and malignant renal cells and assess their possible association with different clinical parameters.
  • Intensity of p27((Kip1)) expression in RCC was negatively correlated with tumor size (Rho = -0.438, P = 0.0051) and associated with pathological stage and grade (P = 0.0488 and < 0.0001, respectively).
  • The patients with symptomatic disease had significantly less marker expression than incidentally discovered tumors (P = 0.0301).
  • Loss of p27((Kip1)) expression, pathological stage, grade and tumor size were the risk-factors for disease recurrence (P = 0.0072, 0.0011, 0.0467 and < 0.0001, respectively) and patient survival (P = 0.0021, 0.0106, 0.0151 and 0.0021, respectively).
  • With Cox multivariate analysis loss of p27((Kip1)) expression (hazard ratio 9.3, P = 0.002) and tumor size (hazard ratio 5.9, P = 0.015) were the predictors of cancer-specific survival.
  • Intensity of the expression is associated with clinical parameters: tumor size, stage, grade and disease presentation.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / genetics. Kidney Neoplasms / genetics. Neoplasm Recurrence, Local / genetics

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):601-7 [12448001.001]
  • [Cites] Urology. 2001 Sep;58(3):477-81 [11549509.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):911-20 [16097446.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3974-86 [15930332.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1245-6 [7489399.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1417-23 [12778072.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):509-17 [15118854.001]
  • [Cites] J Urol. 2005 Jun;173(6):1847 [15879760.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1904-14 [15622584.001]
  • [Cites] Urol Clin North Am. 2003 Aug;30(3):467-80 [12953749.001]
  • [Cites] Nephrol Dial Transplant. 2002 Apr;17(4):573-9 [11917048.001]
  • [Cites] Kidney Int. 2004 Feb;65(2):510-20 [14717921.001]
  • [Cites] BJU Int. 2005 Feb;95(3):310-4 [15679784.001]
  • [Cites] BJU Int. 2005 Mar;95 Suppl 2:8-13 [15759349.001]
  • [Cites] J Urol. 2005 Mar;173(3):680 [15711241.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):631-6 [15517366.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):973-9 [11920465.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5535-41 [16216245.001]
  • [Cites] Urology. 2004 Sep;64(3):611-6 [15351619.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):992-3 [9307205.001]
  • [Cites] J Urol. 2005 Jun;173(6):1853-62 [15879764.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2266-9 [7757974.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):1-9 [16194700.001]
  • (PMID = 17310312.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


16. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • The incidence of malignant colonic intussusception (63%) was significantly higher than that of enteric intussusception (20%), P = 0.001.
  • Primary colon adenocarcinoma (8 of 10 patients, 80%) and malignant lymphoma (2 of 10 patients, 20%) were the two most common underlying malignant lesions in the colon.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Yano H, Kimura Y, Iwazawa T, Takemoto H, Imasato M, Monden T, Okamoto S: Hand-assisted laparoscopic surgery for a large gastrointestinal stromal tumor of the stomach. Gastric Cancer; 2005;8(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopic surgery for a large gastrointestinal stromal tumor of the stomach.
  • We report two cases of large gastrointestinal stromal tumor (GIST) of the stomach that were successfully treated by hand-assisted laparoscopic surgery (HALS).
  • Two patients, a 56-year-old woman and a 60-year-old man, were admitted to our department for the treatment of a large submucosal tumor of the stomach.
  • Hand-assisted laparoscopic wedge resection was safely performed for the diagnosis and treatment of the submucosal tumor of the stomach.
  • HALS may be a good indication for large GISTs of the stomach that are difficult to diagnose preoperatively, whether they are malignant or benign, because it is safe and minimally invasive, promoting rapid recovery.
  • [MeSH-major] Gastrointestinal Stromal Tumors / surgery. Laparoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):297-313 [8946608.001]
  • [Cites] Am J Clin Pathol. 1988 May;89(5):601-10 [3282426.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):207-16 [7530409.001]
  • [Cites] Acta Chir Scand. 1968;134(5):384-91 [5731276.001]
  • [Cites] Am J Clin Pathol. 1993 Oct;100(4):428-32 [8105676.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Dis Colon Rectum. 1993 Sep;36(9):858-61 [8397078.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):830-4 [3402974.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Semin Laparosc Surg. 2001 Jun;8(2):96-103 [11441398.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):887-97 [8394653.001]
  • [Cites] J Gastroenterol. 2003;38(9):896-9 [14564636.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):985-9; discussion 989-90 [1863217.001]
  • [Cites] Surgery. 1994 Nov;116(5):842-6 [7940187.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Surg Endosc. 1994 Aug;8(8):887-9 [7992156.001]
  • [Cites] J Natl Compr Canc Netw. 2004 May;2 Suppl 1:S-1-26; quiz 27-30 [23573667.001]
  • [Cites] Surg Today. 2000;30(2):177-80 [10664344.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 1995 Jul;38(7):681-5; discussion 685-6 [7607025.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):180-3 [12851843.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Surg Today. 2001;31(4):346-9 [11321347.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):632-6 [12167576.001]
  • (PMID = 16086122.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Jung MK, Cho CM, Park SY, Jeon SW, Tak WY, Kweon YO, Kim SK, Choi YH: Endoscopic resection of ampullary neoplasms: a single-center experience. Surg Endosc; 2009 Nov;23(11):2568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An ampullary tumor, whether malignant or not, must be completely resected.
  • A benign adenoma has the potential for malignant transformation.
  • Currently, endoscopic papillectomy with curative intent is increasingly performed for benign papillary tumors.
  • This study aimed to evaluate the outcome of endoscopic papillectomy performed for ampullary tumors at a single center.
  • METHODS: From July 2003 to June 2008, 22 patients with a diagnosis of ampullary tumors determined by endoscopic retrograde cholangiopancreatography (ERCP) were treated using endoscopic resection of the tumors.
  • Endoscopic resection was performed in a radical fashion analogous to polypectomy for colon adenomas.
  • CONCLUSIONS: The findings showed that an endoscopic papillectomy was safe and effective for benign-appearing adenomas with negative biopsy results for a malignancy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chi-Square Distribution. Cohort Studies. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Pancreaticoduodenectomy / methods. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Probability. Reoperation / methods. Retrospective Studies. Risk Assessment. Sphincterotomy, Endoscopic / adverse effects. Sphincterotomy, Endoscopic / methods. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 May;38(5):521-5 [16767591.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):608-13 [16508819.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Surgery. 1987 Apr;101(4):501-4 [3563897.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):367-70 [16111953.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Surg Gynecol Obstet. 1989 Nov;169(5):445-8 [2683151.001]
  • [Cites] Endoscopy. 1988 Aug;20 Suppl 1:227-31 [3168951.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):799-819 [7248908.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):358-65 [3632096.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):187-200 [17245171.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):789-91 [16650539.001]
  • [Cites] Gastrointest Endosc. 2001 Aug;54(2):202-8 [11474391.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):383-93 [2070995.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):757-64 [15557951.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):783-8 [16650538.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • (PMID = 19360365.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Königsrainer I, Steurer W, Witte M, Königsrainer A: Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis. Langenbecks Arch Surg; 2007 Jul;392(4):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis.
  • Extrahepatic isolation of portal vein, hepatic artery and hepatic duct, as well as lymphadenectomy of the liver hilum are generally accepted steps of liver resection, even for metastatic and benign indications.
  • MATERIALS AND METHODS: Thirty-eight consecutive patients with resection for metastases and benign liver tumors were selected.
  • To date, no tumor recurrence was found in the hilum during the follow-up period.
  • Hilar dissection can, thus, be avoided in liver metastasis and benign liver tumors.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1285-90; discussion 1290-1 [10528765.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):43-5 [15786414.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):137-8; author reply 138 [16371749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):582-90 [15798459.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):685-9 [16703653.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):286-91 [9880776.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):202-9 [14745328.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):111-9 [12832973.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):764-7 [7571678.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):704-11; discussion 711-3 [9409569.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):942-5 [8813780.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):121-4 [8653335.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):814-22, discussion 822-3 [16327491.001]
  • (PMID = 17530278.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
  • In normal stomach and colon, beta3Gn-T6 was strongly expressed in the Golgi region of epithelia.
  • Tissue specimens from a familial adenomatous polyposis patient showed a clear correlation between the down-regulation of beta3Gn-T6 expression and the degree of dysplasia/neoplasia.
  • These results suggested that the expression of beta3Gn-T6 is closely regulated during differentiation and dedifferentiation. beta3Gn-T6 would be a useful marker for distinguishing between benign adenomas and premalignant lesions.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. N-Acetylglucosaminyltransferases / genetics. N-Acetylglucosaminyltransferases / physiology
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


21. Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP, Kitsis RN: ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle; 2008 Jun 1;7(11):1640-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.
  • Recently, however, the abundance of ARC was noted to be markedly increased in the epithelium of primary human breast cancers compared with benign breast tissue and to confer chemo- and radiation-resistance.
  • Whether the induction of ARC is specific to breast cancer or a more general feature of neoplasia remains unknown.
  • In this study, we assessed the abundance and subcellular localization of ARC in 21 human colon cancer cell lines and in 44 primary human colon adenocarcinomas and adjacent benign colonic tissue.
  • ARC was present at high levels in most colon cancer cell lines and in almost all primary colon cancers compared with corresponding controls.
  • Levels of ARC in the cytoplasm were increased in well, moderately, and poorly differentiated cancers compared with benign tissue, while levels of nuclear ARC were increased only in moderately differentiated tumors.
  • These results demonstrate that ARC is a novel marker of human colon cancer and suggest that it may be a general feature of epithelial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis Regulatory Proteins / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / metabolism. Muscle Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Cytoplasm / metabolism. Humans. Immunoblotting. Immunohistochemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469522.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NHLBI NIH HHS / HL / R01HL60665; United States / NHLBI NIH HHS / HL / R01HL61550; United States / NHLBI NIH HHS / HL / R01HL80607
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / NOL3 protein, human
  •  go-up   go-down


22. Doll D, Keller L, Maak M, Boulesteix AL, Siewert JR, Holzmann B, Janssen KP: Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis; 2010 May;25(5):573-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival.
  • However, their contribution to tumor formation remains incompletely understood.
  • The aim of the present study was to investigate the regulation of their expression in colon cancer cells and to test the hypothesis that altered CXC-chemokine expression is related to critical clinical parameters, such as survival or metastasis formation.
  • MATERIALS AND METHODS: Expression levels of interleukin-8 (CXCL-8) and growth-related oncogenes 2 and 3 (GRO-2/CXCL-2 and GRO-3/CXCL-3) were quantified using qRT-PCR in 97 patients with completely resected colon carcinoma and correlated with clinical parameters.
  • Moreover, 16 samples of normal mucosa, nine samples of benign adenoma, and 11 samples of liver metastasis were analyzed.
  • Next, the regulation of chemokine expression in response to various stimuli was tested in colon cancer cell lines (HT29, HCT116, CaCO2).
  • RESULTS: Expression of GRO-2, GRO-3, and IL-8 was significantly increased in colon cancer as compared to normal colon tissue.
  • Expression of GRO-2 and GRO-3 was already enhanced in premalignant adenomas, and GRO-3 was significantly down-regulated in liver metastasis as compared to the primary tumor.
  • Finally, all chemokines were strongly induced by IL-1alpha in the colon cancer cell lines tested, indicating a potential link to inflammatory processes.
  • CONCLUSION: In accordance with earlier findings, we report here a significantly increased expression of GRO-2, GRO-3, and IL-8 in colon carcinoma as compared to normal tissue.
  • [MeSH-major] Chemokine CXCL2 / genetics. Chemokines, CXC / genetics. Colonic Neoplasms / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2002 Nov;72(5):847-55 [12429706.001]
  • [Cites] ILAR J. 1999 Sep;40(4):175-182 [11406696.001]
  • [Cites] J Gastroenterol. 1994 Aug;29(4):423-9 [7951851.001]
  • [Cites] J Lab Clin Med. 1998 Aug;132(2):97-103 [9708570.001]
  • [Cites] World J Gastroenterol. 2007 Oct 7;13(37):4996-5002 [17854143.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3581-4 [16101183.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3298-304 [11595728.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):437-43 [15734970.001]
  • [Cites] Melanoma Res. 1999 Aug;9(4):383-7 [10504057.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):397-407 [1497091.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1910-3 [14696431.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):391-402 [15883783.001]
  • [Cites] J Cell Biochem. 1988 Feb;36(2):185-98 [3356754.001]
  • [Cites] Cancer Immunol Immunother. 1994 Mar;38(3):167-70 [8124684.001]
  • [Cites] Biochemistry. 1997 Mar 4;36(9):2716-23 [9054580.001]
  • [Cites] Melanoma Res. 1995 Jun;5(3):179-81 [7640519.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):783-9 [10213213.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1214-23 [9322516.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):2069-77 [7500052.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):492-504 [12145803.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3711-21 [10589791.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2290-9 [10786697.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):317-22 [15958053.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20431-7 [11923281.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9 [17062666.001]
  • [Cites] Exp Dermatol. 1998 Dec;7(6):335-41 [9858136.001]
  • [Cites] Surg Oncol. 1992 Aug;1(4):323-9 [1341267.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):1039-52 [18045955.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2735-40 [10914718.001]
  • [Cites] J Leukoc Biol. 1997 Nov;62(5):554-62 [9365108.001]
  • [Cites] Cytokine. 2000 Jan;12(1):78-85 [10623446.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2747-56 [17363596.001]
  • [Cites] Mol Med. 2001 Aug;7(8):523-34 [11591888.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):226-44 [18579287.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):481-95 [15563311.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1970-6 [15545974.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5346-55 [17000667.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12085-93 [12556523.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Cytokines. 1992;4:96-116 [1335322.001]
  • (PMID = 20162422.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CXCL2 protein, human; 0 / CXCL3 protein, human; 0 / Chemokine CXCL2; 0 / Chemokines, CXC; 0 / Interleukin-8
  •  go-up   go-down


23. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Gräff A, Boland CR, Arnold R, Blum HE: Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer; 2008 Oct 1;123(7):1556-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.
  • To better understand the molecular pathogenesis of neuroendocrine tumors (NET), we investigated the molecular and clinical characteristics of malignant poorly differentiated colorectal NET and compared these findings with sporadic CRC and well-differentiated benign and malignant fore-/midgut NET.
  • Tumors were analyzed and correlated for microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP).
  • A total of 34 malignant poorly differentiated colorectal NET, 38 well-differentiated benign and malignant fore-/midgut-NET and 150 sporadic colorectal cancers (CRC) with known MSI status were investigated.
  • Of the 34 colorectal NET, 0/1 of the MSI-H, 3/5 (60%) of the MSI-L and 13/19 (68%) of the MSS tumors were CIMP+ (p = 0.17).
  • Besides the location in the colon, Ki-67 predicted poor outcome in NET (p < 0.0001).
  • Main differences between malignant well-differentiated and poorly differentiated NET are the Ki-67 proliferation rate and differential methylation in tumor-associated genes.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Neuroendocrine Tumors / genetics. Neuroendocrine Tumors / mortality

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2157-64 [17278096.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):805-15 [15459661.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Nat Med. 1996 Mar;2(3):281-2 [8612223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2545-50 [9122232.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):50-6 [9591634.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1223 [9652567.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):11-6 [10389971.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):855-60 [15613458.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):256-60 [15842051.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):145-9 [18058263.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):38-45 [11790979.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Feb;15(2):139-43 [12560757.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):924-34 [12584572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1367-73 [12629131.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):181-6 [14639103.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):570-6 [10747315.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):549-56 [10998653.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1097-103 [11021813.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4073-81 [11051259.001]
  • [Cites] Oncology. 2000 Sep;59(3):229-37 [11053991.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4146-56 [11095446.001]
  • [Cites] Gut. 2001 Apr;48(4):536-41 [11247899.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5905-10 [11479232.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Neuroendocrinology. 2005;81(1):1-9 [15809513.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71 [16234004.001]
  • [Cites] Int J Colorectal Dis. 2006 Apr;21(3):221-30 [16485142.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • (PMID = 18646189.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA072851-13
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS187521; NLM/ PMC2851204
  •  go-up   go-down


24. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • MATERIALS AND METHODS: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down


25. Glasgow SC, Birnbaum EH, Lowney JK, Fleshman JW, Kodner IJ, Mutch DG, Lewin S, Mutch MG, Dietz DW: Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum; 2005 Aug;48(8):1581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors: a diagnostic and therapeutic challenge.
  • PURPOSE: Tumors occurring in the retrorectal space are heterogeneous and uncommon.
  • This study examined the diagnosis, treatment, and outcome of retrorectal tumors at a tertiary referral center.
  • RESULTS: Thirty-four patients with retrorectal tumors were treated.
  • Malignant tumors comprised 21 percent.
  • Accuracy of magnetic resonance vs. computed tomographic imaging for specific histologic tumor type was 28 vs. 18 percent, respectively.
  • All benign tumors were resected with normal histologic margins and none recurred (median follow-up, 22 months).
  • CONCLUSIONS: Retrorectal tumors remain a diagnostic and therapeutic challenge.
  • Whereas benign retrorectal tumors can be completely resected, curative resection of malignant retrorectal tumors remains difficult.
  • [MeSH-minor] Abdomen / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Blood Loss, Surgical. Blood Transfusion. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Perineum / surgery. Proctoscopy. Prospective Studies. Rectum / surgery. Retrospective Studies. Sex Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937630.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Atallah S, Albert M, Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc; 2010 Sep;24(9):2200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the clinical application of this technique and present preliminary data that show TAMIS to be an effective tool for resection of both malignant and benign lesions of the rectum.
  • Patients with biopsy-proven malignant lesions were required to undergo endorectal ultrasound preoperatively to determine tumor stage.
  • The average distance from the anal verge was 9.3 cm and the mean tumor diameter confirmed by pathology measured 2.93 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] World J Surg. 2009 May;33(5):1015-9 [19116734.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 2009 Jun;52(6):1107-13 [19581854.001]
  • [Cites] Colorectal Dis. 2007 Jul;9(6):553-8 [17573752.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):445-9 [19565297.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):227-32 [17098653.001]
  • [Cites] Gastrointest Endosc. 2009 Jul;70(1):193-4 [19559847.001]
  • [Cites] Leber Magen Darm. 1985 Nov;15(6):271-9 [4079630.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1733-40 [19412642.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1376-80 [14571741.001]
  • [Cites] Minerva Chir. 2009 Aug;64(4):355-64 [19648856.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Urology. 2009 Oct;74(4):805-12 [19643465.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):795-9 [17032328.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Int Semin Surg Oncol. 2006 May 04;3:13 [16674824.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):372-8 [11147912.001]
  • [Cites] Colorectal Dis. 2007 Mar;9(3):229-34 [17298620.001]
  • [Cites] Ann Surg. 2009 May;249(5):776-82 [19387326.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Aug;19(4):495-9 [19630589.001]
  • [Cites] Surg Endosc. 2009 May;23(5):1138-41 [19263120.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 20174935.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


28. Nowicki MJ, Bishop PR, Subramony C, Wyatt-Ashmead J, May W, Crawford M: Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion. J Pediatr Gastroenterol Nutr; 2005 Nov;41(5):600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic chicken-skin mucosa in children with polyps is not a preneoplastic lesion.
  • Colonic polyps are common both in adults and children; however, the malignant potential varies according to the type of polyp.
  • To determine whether CSM represents a preneoplastic lesion, we studied endoscopic colonic mucosal biopsies for markers of cell replication (Ki-67) and malignant transformation (p53) in mucosal biopsies of CSM, normal colonic tissue, tubular adenomas, and adenocarcinomas.
  • The degree of Ki-67-positive staining cells was similar for CSM and normal colonic tissue, whereas there was significantly increased staining for both tubular adenomas and adenocarcinomas.
  • There was no evidence of p53 staining in CSM and normal colonic mucosa, whereas there was varying degrees of staining in tubular adenomas and adenocarcinomas.
  • The association of CSM with benign juvenile polyps and the absence of histologic markers for increased replication and malignant transformation support the notion that this endoscopic finding is not preneoplastic.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Intestinal Mucosa / pathology. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / analysis. Biopsy. Child. Child, Preschool. Colon / pathology. Colonoscopy. Female. Humans. Immunohistochemistry. Male. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16254516.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


30. Hong R, Lim SC: Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report. World J Gastroenterol; 2009 Jul 14;15(26):3315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report.
  • A granular cell tumor (GCT) is a benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin.
  • In addition to the tumor, endoscopic examination revealed the presence of a 5-mm-polyp in the descending colon and multiple tiny polyps in the sigmoid colon and rectum.
  • Histological examination demonstrated a cecal tumor 1.5 cm x 1.0 cm x 0.7 cm with a hard consistency; in cut sections, mixed cells with yellowish and whitish portions were seen.
  • The tumor was located between the mucosa and subserosa, and was composed of plump histiocyte-like tumor cells with abundant granular eosinophilic cytoplasm, which were immunoreactive for S-100 protein, vimentin, neuron-specific enolase, inhibin-alpha and calretinin.
  • The tumor showed extensive hyalinization and focal dystrophic calcification.
  • Extensive hyalinization and calcification showing involution of tumor cells suggest benign clinical behavior of GCT.
  • [MeSH-major] Calcinosis / pathology. Cecum / pathology. Granular Cell Tumor / pathology. Hyalin / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Calbindin 2. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Humans. Male. Middle Aged. Phosphopyruvate Hydratase. S100 Calcium Binding Protein G. S100 Proteins. Vimentin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ugeskr Laeger. 2006 May 22;168(21):2080-1 [16768929.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):164-9 [9176790.001]
  • [Cites] J Craniofac Surg. 2008 Nov;19(6):1691-4 [19098584.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1200-3 [11688581.001]
  • [Cites] J Gastroenterol. 2003;38(4):385-9 [12743780.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2452-4 [15285042.001]
  • [Cites] Mt Sinai J Med. 1979 Mar-Apr;46(2):195-8 [220528.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Apr;65(4):427-35 [2834681.001]
  • [Cites] Am J Gastroenterol. 1989 Jun;84(6):656-9 [2543214.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1785-7 [8213726.001]
  • [Cites] Pathologica. 1995 Apr;87(2):175-8 [8532413.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Dec;80(6):687-97 [8680977.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jan;94(1):27-32 [9028140.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):73-4 [18386247.001]
  • (PMID = 19598311.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2710791
  •  go-up   go-down


31. Zmora O, Benjamin B, Reshef A, Neufeld D, Rosin D, Klein E, Ayalon A, Shpitz B: Laparoscopic colectomy for colonic polyps. Surg Endosc; 2009 Mar;23(3):629-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colonic polyps.
  • BACKGROUND: Benign colonic polyps not amenable to colonoscopic resection or those containing carcinoma require surgical excision.
  • The aim of this study was to review our experience with the laparoscopic approach for retrieval of colonic polyps with specific emphasis on safety, feasibility, and tumor localization.
  • METHODS: Retrospective chart review of all patients who underwent laparoscopic colectomy for colonic polyps was performed.
  • RESULTS: Forty-nine patients (22 males, 27 males, mean age 66 years) underwent laparoscopic colectomy for colonic polyps.
  • Indications for surgery were presumably benign polyps in 38 patients, and superficial carcinoma in a polyp, diagnosed by colonoscopy, in 11; twenty-three patients underwent preoperative localization procedures.
  • In 7 of the 38 patients with presumably benign lesion, colon cancer was diagnosed in the colectomy specimen.
  • CONCLUSIONS: Laparoscopic surgery for the treatment of colonic polyps seems to be feasible and safe, with a low complication rate.
  • Tumor localization is crucial for adequate resection.
  • Although one-fifth of presumably benign polyps harbored cancer, none of these patients had positive lymph nodes.
  • [MeSH-major] Colectomy / methods. Colonic Polyps / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Apr;30(4):605-11 [16555023.001]
  • [Cites] Surg Endosc. 2002 May;16(5):808-11 [11997827.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):177-81 [12892794.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1491-5 [17534547.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1353-5 [10528779.001]
  • [Cites] Ann Surg. 2006 Jun;243(6):730-5; discussion 735-7 [16772776.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003145 [16034888.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1197-9 [18062067.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):819-22 [10378609.001]
  • [Cites] Am J Surg. 2006 Nov;192(5):644-8 [17071200.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • (PMID = 19067054.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


32. Osunkoya AO, Cohen C, Lawson D, Picken MM, Amin MB, Young AN: Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol; 2009 Feb;40(2):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a recent oligonucleotide microarray study, we identified claudin-7 and claudin-8 as candidate markers to distinguish chromophobe renal cell carcinoma from other renal tumors, including oncocytoma.
  • Distinction of these lesions can be difficult by light microscopy but is clinically important because chromophobe renal cell carcinoma has malignant biological potential, whereas renal oncocytoma is benign.
  • Claudin-7 and claudin-8 expression was studied by immunohistochemistry in 11 chromophobe renal cell carcinomas and 17 oncocytomas using formalin-fixed paraffin-embedded tissue sections of tumor with adjacent nonneoplastic kidney.
  • Specificity was verified by negative control reactions without primary antibody and appropriate membranous staining patterns in positive control tissues (colon carcinoma and adjacent nonneoplastic kidney).
  • [MeSH-minor] Biomarkers, Tumor / analysis. Claudins. Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity


33. Ishikawa K, Hirashita T, Araki K, Kitano M, Matsuo S, Matsumata T, Kitano S: A case of retroperitoneal mucinous cystadenoma treated successfully by laparoscopic excision. Surg Laparosc Endosc Percutan Tech; 2008 Oct;18(5):516-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found a smooth and thin-walled cystic tumor that displaced the descending colon to the right and arose from the retroperitoneum, loosely adhering to the psoas muscle.
  • We successfully extirpated the tumor laparoscopically.
  • The histologic diagnosis was benign mucinous cystadenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936681.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Pagnotta E, Calonghi N, Boga C, Masotti L: N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. Anticancer Drugs; 2006 Jun;17(5):521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells.
  • Both agents show the same anti-proliferative effects by arresting colon cancer cell growth in G0/G1.
  • The effects of NMF and 9-HSA on growth, differentiation and invasiveness of HT29, a colon cancer cell line, have been compared by using immunoprecipitation analysis, confocal microscopy, enzyme assays and invasiveness tests.
  • Evidence is presented that the arrest in early G0/G1 induced by 9-HSA is associated with the conversion of HT29 characteristics to those of a more benign phenotype, whereas the arrest in the late G1 in response to NMF is not followed by a decrease in tumorigenicity.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Formamides / pharmacology. Stearic Acids / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cytoskeleton / drug effects. Humans. Microscopy, Confocal

  • Hazardous Substances Data Bank. N-METHYLFORMAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702808.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Formamides; 0 / Stearic Acids; 3384-24-5 / 9-hydroxystearic acid; XPE4G7Y986 / methylformamide
  •  go-up   go-down


35. Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ: Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol; 2009 Mar;34(3):821-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated levels of periostin have been implicated as playing important roles in tumor invasion and metastasis in various tissues.
  • We also evaluated periostin expression in human CRC specimens (n=15) using immunohistochemistry, and measured expression of periostin mRNA in 7 CRC tissue samples, matched normal tissues and in 4 colon cancer cell lines by RT-PCR.
  • The serum levels of periostin in CRC patients (40.9+/-15.4 ng/ml) were significantly elevated compared to that in healthy volunteers (21.0+/-7.3 ng/ml, P<0.0001) and benign colorectal polyps or adenomas (22.4+/-8.5 ng/ml, P<0.0001).
  • Interestingly, periostin mRNA was highly upregulated in CRCs in comparison with matched normal tissues, and no expression of periostin mRNA was detected in 4 colon cancer cell lines.
  • Periostin may be produced by the stromal cells surrounding the tumor, but not by the CRC cells themselves.
  • [MeSH-major] Biomarkers, Tumor / blood. Cell Adhesion Molecules / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212687.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  •  go-up   go-down


36. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • RESULTS: In the present study were observed 6 cases of carcinoids localized in ileum, cecum and sigmoid colon, 1 case of gastrinoma in pancreatic head localization, 1 case of insulinoma localized in pancreatic tail, 1 case of vipoma localised in pancreatic head, 2 cases of nesidioblastoma and 1 case of microcystic adenoma with neuroendocrine differentiation in pancreatic tail localization and 1 case of nonspecific apudoma observed in ileum.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


37. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem; 2006 Nov 17;281(46):34936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models.
  • On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties.
  • IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and breast carcinoma cells.
  • On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production.
  • In HCA7 colon and C4-2 prostate carcinoma cells, ERBB2 is constitutively activated in a ligand-independent manner, whereas IGF1R-beta and PDGFR-beta require ligand interaction for activation.
  • [MeSH-minor] Breast Neoplasms / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Humans. Male. Prostatic Neoplasms / metabolism. Signal Transduction


38. Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P: Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch; 2007 Aug;451 Suppl 1:S9-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.
  • The gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are composed of cells with a neuroendocrine phenotype.
  • Well-differentiated tumors, well-differentiated carcinomas, poorly differentiated carcinomas, functioning tumors (with a hormonal syndrome), and nonfunctioning tumors are identified.
  • To predict their clinical behavior, these neuroendocrine tumors are classified on the basis of their clinicopathological features, including size, local invasion, angioinvasion, proliferative activity, histological differentiation, and metastases, into neoplasms with benign, uncertain, low-grade malignant and high-grade malignant behavior.
  • In addition, a tumor/nodes/metastases classification and a grading system are presented.
  • [MeSH-major] Digestive System Neoplasms / classification. Digestive System Neoplasms / pathology. Neuroendocrine Tumors / classification. Neuroendocrine Tumors / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1984 Dec;8(12):917-24 [6097131.001]
  • [Cites] Surgery. 1986 Jun;99(6):671-8 [2424108.001]
  • [Cites] Am J Surg. 1980 May;139(5):682-90 [6258453.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Am J Surg. 1964 Aug;108:132-41 [14195205.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Surgery. 1992 Apr;111(4):466-71 [1557693.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):517-22 [11914632.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1329-34 [1678681.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Lancet. 1977 Mar 26;1(8013):666-8 [66472.001]
  • [Cites] Medicine (Baltimore). 1949 Dec;28(4):427-47 [15399004.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):605-10 [12734754.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):811-7 [12766586.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):394-8 [16418841.001]
  • [Cites] Ann Surg. 1981 Feb;193(2):185-90 [6258500.001]
  • [Cites] Hum Pathol. 1985 Jul;16(7):746-51 [3891579.001]
  • [Cites] Regul Pept. 1987 Jan;17(1):9-29 [2882565.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1075-82 [9298884.001]
  • [Cites] Gastroenterol Clin North Am. 1989 Dec;18(4):671-93 [2575601.001]
  • [Cites] Endocr Pathol. 1995 Autumn;6(3):229-237 [12114744.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):475-89 [2869609.001]
  • [Cites] Yale J Biol Med. 1996 Jan-Feb;69(1):69-74 [9041691.001]
  • [Cites] Hum Pathol. 1979 May;10(3):350-3 [89070.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1581-7 [17122515.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):51-67 [6258288.001]
  • [Cites] Neuroendocrinology. 2005;81(6):400-4 [16276118.001]
  • [Cites] Gastroenterology. 1968 Dec;55(6):677-86 [4302500.001]
  • [Cites] Br J Surg. 1993 Apr;80(4):502-4 [8495322.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S39-46 [17684763.001]
  • [Cites] Am J Pathol. 1984 Nov;117(2):167-70 [6093542.001]
  • [Cites] Surg Today. 1997;27(2):112-9 [9017986.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):677-82 [222222.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):248-54 [15517368.001]
  • [Cites] N Engl J Med. 1986 Jul 31;315(5):287-91 [3014338.001]
  • [Cites] J Clin Gastroenterol. 2001 Aug;33(2):154-6 [11468445.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1233-9 [15316325.001]
  • [Cites] Ann Surg. 1981 Dec;194(6):692-7 [7030236.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Ann Surg. 1989 Apr;209(4):396-404 [2930285.001]
  • [Cites] Am J Clin Pathol. 1989 Jan;91(1):52-6 [2462784.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1975;365(4):275-88 [46649.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):952-5 [10970700.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2204-10 [11596039.001]
  • [Cites] Mayo Clin Proc. 1974 Jan;49(1):44-51 [4149030.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1985;405(3):311-23 [2579503.001]
  • [Cites] Scand J Gastroenterol. 1980;15(2):129-35 [6247758.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):588-94 [15832081.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):468-79 [3532971.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):428-39 [10473967.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Ann Surg. 1983 May;197(5):594-607 [6847279.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2029-37 [6271390.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):175-80 [8119718.001]
  • [Cites] Mayo Clin Proc. 1990 Nov;65(11):1399-407 [1700240.001]
  • [Cites] Dig Dis Sci. 1991 Jul;36(7):933-42 [2070707.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Dec;17(4):379-88 [10089055.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2540-5 [2655873.001]
  • [Cites] Am J Gastroenterol. 1981 Aug;76(2):125-31 [6272569.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):963-5 [14645360.001]
  • [Cites] J Pediatr Surg. 1985 Dec;20(6):734-6 [3003324.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):560-74 [16699310.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 1979 Nov;44(5):1853-9 [227580.001]
  • [Cites] Am J Surg. 1985 Jun;149(6):775-9 [2409828.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1531-6 [17122508.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1860-74 [6627205.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1587-95 [15742328.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):25-31 [6691547.001]
  • [Cites] N Engl J Med. 1979 Aug 9;301(6):285-92 [377080.001]
  • [Cites] Gut. 2007 May;56(5):637-44 [17135306.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):43-50 [17270665.001]
  • [Cites] Mol Endocrinol. 1989 Oct;3(10):1589-95 [2691879.001]
  • [Cites] Mayo Clin Proc. 1976 Jul;51(7):417-29 [180358.001]
  • [Cites] J Surg Oncol. 1991 Mar;46(3):174-7 [1849211.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):207-16 [920868.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):772-8 [3026608.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):481-8 [8103250.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2894-9 [8199985.001]
  • [Cites] Am J Surg Pathol. 1984 Aug;8(8):607-14 [6205601.001]
  • [Cites] Am J Surg. 1979 Jan;137(1):142-8 [215044.001]
  • [Cites] Mayo Clin Proc. 1991 Jul;66(7):711-9 [1677058.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2097-108 [6435852.001]
  • [Cites] Scand J Gastroenterol Suppl. 1979;53:79-91 [290036.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1086-93 [9070484.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Am J Surg. 1983 Jul;146(1):124-32 [6869670.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):263-81 [2820062.001]
  • [Cites] Virchows Arch. 2000 Mar;436(3):217-23 [10782879.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):969-75 [15958864.001]
  • [Cites] Dis Colon Rectum. 1972 Sep-Oct;15(5):383-91 [4561188.001]
  • [Cites] Digestion. 1995;56(6):455-62 [8536814.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):8-18 [1531004.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):776-81 [11787850.001]
  • [Cites] Pathol Res Pract. 1992 Aug;188(6):751-6 [1437839.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Gut. 2002 Aug;51(2):184-90 [12117877.001]
  • [Cites] Ann Surg. 1955 Oct;142(4):709-23; discussion, 724-8 [13259432.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Jun;56(6):1236-42 [6132927.001]
  • [Cites] Mayo Clin Proc. 1978 Jan;53(1):19-23 [625140.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] J Clin Pathol. 2001 Nov;54(11):880-2 [11684726.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):223-31 [9665483.001]
  • [Cites] Gastroenterology. 1985 Mar;88(3):798-803 [2981755.001]
  • [Cites] Am J Gastroenterol. 1986 Jan;81(1):33-7 [2867674.001]
  • [Cites] Am J Clin Pathol. 1987 Aug;88(2):153-61 [2887104.001]
  • [Cites] Arch Pathol Lab Med. 1990 Jul;114(7):700-4 [1694655.001]
  • [Cites] Pathol Res Pract. 1988 Apr;183(2):155-68 [2898775.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):9-14 [2294850.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):327-333 [12114794.001]
  • [Cites] Histopathology. 1992 Sep;21(3):215-23 [1356906.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1637-49 [7768367.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):183-5 [8459042.001]
  • [Cites] World J Gastroenterol. 2006 Sep 14;12(34):5440-6 [17006979.001]
  • [Cites] Am J Surg Pathol. 1986 May;10(5):348-57 [2422964.001]
  • [Cites] Am J Surg. 1980 Jul;140(1):119-25 [6249135.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2264-71 [16258711.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):251-5 [9500228.001]
  • [Cites] Surgery. 1974 Apr;75(4):597-609 [4366135.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1551-8 [14657715.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Med Pediatr Oncol. 2002 Jan;38(1):65-6 [11835243.001]
  • [Cites] N Engl J Med. 1990 Mar 15;322(11):723-7 [1968616.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):994-1006 [7681798.001]
  • [Cites] Lancet. 1963 Feb 2;1(7275):238-9 [14000847.001]
  • [Cites] Diabetes. 1979 Oct;28(10):925-36 [383556.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2320-2 [8402445.001]
  • [Cites] Br J Surg. 1979 Jun;66(6):373-8 [223712.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):139-48 [9700573.001]
  • [Cites] Postgrad Med J. 1995 Aug;71(838):485-6 [7567757.001]
  • [Cites] Histopathology. 1986 Feb;10(2):119-33 [3007321.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):752-60 [11395552.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1677-82 [18059224.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):499-506 [17033797.001]
  • [Cites] Virchows Arch. 2007 Aug;451 Suppl 1:S29-38 [17684762.001]
  • [Cites] Gastroenterology. 1997 Sep;113(3):773-81 [9287968.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Apr;52(4):820-2 [7204545.001]
  • [Cites] World J Surg. 1996 Feb;20(2):183-8 [8661815.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):1-9 [2750701.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(3):263-9 [6115499.001]
  • (PMID = 17684761.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 176
  •  go-up   go-down


39. Hajdú N, Zsoldos P, Neuberger G: [Rectum tumor diagnosed by subcutaneous emphysema of the chest]. Magy Seb; 2009 Oct;62(5):308-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rectum tumor diagnosed by subcutaneous emphysema of the chest].
  • BACKGROUND: Various benign and malignant thoracic or abdominal diseases can cause subcutaneous emphysema on the chest, pneumomediastinum or pneumopericardium.
  • To date only 7 cases have been reported on perforation of the sigmoid colon or the rectum presenting with these rare symptoms.
  • Further examination revealed that this was caused by a rectal tumor causing large bowel obstruction and a consequent perforation of the transverse colon.
  • [MeSH-major] Colonic Diseases / surgery. Intestinal Obstruction / surgery. Rectal Neoplasms / complications. Rectal Neoplasms / diagnosis. Subcutaneous Emphysema / etiology


40. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis.
  • To better characterize the role of SERCA3 in colon carcinogenesis, its expression has been investigated in colonic epithelium, benign lesions, adenomas, and adenocarcinomas.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • Inhibition of Sp1-like factor-dependent transcription blocked SERCA3 expression during cell differentiation, and SERCA3 expression was induced by the expression of dominant-negative TCF4 in colon cancer cells.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.
  • In conclusion, intracellular calcium homeostasis becomes progressively anomalous during colon carcinogenesis as reflected by deficient SERCA3 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Calcium / metabolism. Calcium-Transporting ATPases / biosynthesis. Colonic Neoplasms / enzymology. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Blotting, Western. Cell Line, Tumor. Cell Transformation, Neoplastic. Colonic Polyps / enzymology. Cytoskeletal Proteins / genetics. DNA-Binding Proteins. Endoplasmic Reticulum / metabolism. Humans. Immunohistochemistry. Sarcoplasmic Reticulum Calcium-Transporting ATPases. TCF Transcription Factors. Trans-Activators / genetics. Transcription Factor 7-Like 2 Protein. Transcription Factors. Transfection. Transgenes. beta Catenin

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


41. Nagy A, Kovacs T, Lóderer Z: Experiences with PPH gun stapled ileo or coloanal anastomoses after ultralow rectal resections and proctocolectomies with J pouch reconstructions. Acta Chir Iugosl; 2006;53(2):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On 47 totalcolectomised FAP and UC patients and 9 low rectal benign or clinically T1 or T2N0 rectal tumor resection there was only 5 radiologically proven anastomotic leakadge without serious septic complications.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Ileum / surgery. Proctocolectomy, Restorative. Rectum / surgery. Surgical Stapling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139887.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


42. Terzi C, Unek T, Sağol O, Yilmaz T, Füzün M, Sökmen S, Ergör G, Küpelioğlu A: Is rectal washout necessary in anterior resection for rectal cancer? A prospective clinical study. World J Surg; 2006 Feb;30(2):233-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Implantation of exfoliated malignant cells has been suggested as a possible mechanism of tumor recurrence in colorectal anastomoses that might be prevented by cytocidal washout.
  • METHODS: Between May 1999 and March 2004, 96 patients with carcinoma of the rectum and distal sigmoid colon undergoing anterior resection under the care of three surgeons (only one of whom routinely performed rectal washout) were prospectively studied.
  • The fluid was then classified as "acellular," "malignant cells identified," or "benign cells identified" by pathologists.
  • [MeSH-major] Colectomy / methods. Neoplasm Recurrence, Local / prevention & control. Neoplasm Seeding. Peritoneal Lavage / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Reference Values. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Dec 1;52(11):1986-92 [6354419.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Ann R Coll Surg Engl. 1979 Jul;61(4):251-7 [382965.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Jan;71(1):54-6 [2923422.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 1987 Nov;74(11):1049-52 [3690235.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Surg Gynecol Obstet. 1988 Apr;166(4):357 [3353834.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):164-7 [3971822.001]
  • [Cites] Acta Chir Belg. 1994 Sep-Oct;94(5):258-62 [7976066.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):389-402 [12626917.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):206-7 [11856135.001]
  • [Cites] Dis Colon Rectum. 1985 Apr;28(4):260-1 [3979229.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Br J Surg. 1989 Apr;76(4):331-4 [2541860.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):291-6 [14991490.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Surg Today. 1997;27(5):457-9 [9130352.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Ann Med. 1997 Apr;29(2):91-3 [9187224.001]
  • [Cites] Dis Colon Rectum. 1998 Nov;41(11):1432-4 [9823812.001]
  • [Cites] Br J Surg. 1984 Feb;71(2):98-100 [6692125.001]
  • [Cites] Br J Surg. 1982 May;69(5):275-6 [7074339.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 16425079.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Gonçalves AJ, Carvalho LH, Serdeira K, Nakai MY, Malavasi TR: Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells. Sao Paulo Med J; 2007 Sep 6;125(5):289-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells.
  • CONTEXT AND OBJECTIVE: When null, the mu and theta genes of the glutathione S-transferase system (GSTM1 and GSTT1, respectively) are related to malignant tumors affecting the lungs, colon, prostate, bladder and head and neck.
  • The aim of this study was to compare the frequencies of these genes in patients with benign and malignant tumors of the thyroid gland.
  • DESIGN AND SETTINGS: This was a cross-sectional clinical trial carried out in the Head and Neck Surgery Division, Faculdade de Medicina da Santa Casa de São Paulo.
  • METHODS: Samples of thyroid tissue were collected from 32 patients and divided into two groups: benign tumor (A) and malignant tumor (B).
  • RESULTS: The B group presented four cases of positive genotyping for both genes, seven positive for GSTT1 and negative for GSTM1, two negative for GSTT1 and positive for GSTM1, and only one case of double negative.
  • CONCLUSION: In this study, there was no relationship between the presence of the GSTT1 and GSTM1 genes and the benign and malignant thyroid tumors.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Cross-Sectional Studies. Female. Genotype. Humans. Male

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094897.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


44. Petersen M, Evert M, Schneider-Stock R, Pross M, Rüschoff J, Roessner A, Lippert H, Meyer F: Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC). Pathol Res Pract; 2009;205(11):801-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic tumor lesions of the pancreas are relatively uncommon.
  • Advances in imaging and pathohistology, including immunohistochemistry, have led to the detection and classification of novel tumor entities.
  • One of these classified cystic neoplasms of the pancreas is serous oligocystic adenoma (SOIA), a rare and benign tumor lesion.
  • He had a medical history significant for subtotal colectomy because of a synchronous double colonic carcinoma.
  • Both tumor tissue specimens had been characterized for a high level of microsatellite instability (MSI) and loss of hMLH1, as well as for a corresponding germ line mutation in hMLH1 gene, leading to the diagnosis of hereditary non-polyposis associated colon cancer (HNPCC).
  • The case is remarkable since the SOIA revealed MSI and loss of hMLH1 protein in the tumor cells that has never been reported for this tumor type.


45. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, some studies have suggested that SIRT1 could be over-expressed in breast, prostate and colon cancers and up-regulated SIRT1 inactivates p53 by deacetylation.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


46. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • The majority of colorectal GCT involved the right colon (19/26, 73%) ranging in size from 0.2 to 1.8 cm (mean 0.6 cm).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • Although infrequently found in the colorectum, colorectal GCT typically presents incidentally on routine colonoscopy and involves the right colon; it is not over-represented in AA patients.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


47. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA, Kallioniemi A, Meling GI, Skotheim RI, Rognum TO, Thiis-Evensen E, Lothe RA: Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. J Transl Med; 2008;6:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylated MAL gene - a silent marker of early colon tumorigenesis.
  • BACKGROUND: Tumor-derived aberrantly methylated DNA might serve as diagnostic biomarkers for cancer, but so far, few such markers have been identified.
  • The aim of the present study was to investigate the potential of the MAL (T-cell differentiation protein) gene as an early epigenetic diagnostic marker for colorectal tumors.
  • Immunohistochemical analysis of MAL was done using normal colon mucosa samples (n = 5) and a tissue microarray with 292 colorectal tumors.
  • Furthermore, removal of the methylation re-induced gene expression in colon cancer cell lines.
  • Finally, MAL protein was expressed in epithelial cells of normal colon mucosa, but not in the malignant cells of the same type.
  • CONCLUSION: Promoter hypermethylation of MAL was present in the vast majority of benign and malignant colorectal tumors, and only rarely in normal mucosa, which makes it suitable as a diagnostic marker for early colorectal tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. DNA Methylation. Membrane Transport Proteins / genetics. Myelin Proteins / genetics. Proteolipids / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 May 29;22(22):3463-71 [12776198.001]
  • [Cites] J Histochem Cytochem. 2003 May;51(5):665-74 [12704214.001]
  • [Cites] J Obstet Gynaecol Res. 2004 Feb;30(1):53-8 [14718022.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] J Cell Biol. 1999 Apr 5;145(1):141-51 [10189374.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2029-33 [10232580.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3730-40 [10446989.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):192-206 [15633136.001]
  • [Cites] Neoplasia. 2005 Feb;7(2):99-108 [15802015.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):797-808 [16952549.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1618-26; discussion 1626-7 [17762966.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] DNA Cell Biol. 1997 Mar;16(3):245-55 [9115633.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):2077-84 [9528996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Lab Invest. 2001 Feb;81(2):217-29 [11232644.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):574-9 [11870540.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1747-57 [14652236.001]
  • (PMID = 18346269.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL protein, human; 0 / Membrane Transport Proteins; 0 / Myelin Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteolipids
  • [Other-IDs] NLM/ PMC2292685
  •  go-up   go-down


48. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
  • The gene SASH1 (SAM- and SH3-domain containing 1) has originally been identified as a candidate tumour suppressor gene in breast cancer.
  • We have used quantitative real-time PCR to investigate the expression of SASH1 in tissue samples from 113 patients with colon carcinoma, and compared the expression with 15 normal colon tissue samples.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Expression levels of SASH1 were strongly and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases.
  • Overall, 48 out of 113 primary colon tumours showed SASH1 expression that was at least 10-fold lower than the levels found in normal colon tissue.
  • [MeSH-major] Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


49. Tedesco MM, Curet MJ: Laparoscopic-assisted colectomy for colon cancer. Expert Rev Med Devices; 2006 Jul;3(4):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colectomy for colon cancer.
  • Laparoscopic-assisted colectomy (LAC) for colon cancer was first described in 1991.
  • Unlike other laparoscopic procedures used to treat benign disease, the LAC for colon cancer has been slow to gain acceptance for a variety of reasons.
  • Recently, several large, randomized controlled trials have demonstrated that LACs are comparable with open colectomies with respect to oncological issues such as survival, port-site metastases and tumor recurrence.
  • Moreover, there are significant patient benefits with the use of LAC including duration of analgesic use, return of bowel function, length of stay and return to normal activity.
  • [MeSH-major] Colectomy. Colonic Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Humans. Length of Stay. Neoplasm Recurrence, Local. Quality of Life. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866638.001).
  • [ISSN] 1743-4440
  • [Journal-full-title] Expert review of medical devices
  • [ISO-abbreviation] Expert Rev Med Devices
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


50. Shantha Kumara HM, Hoffman A, Kim IY, Feingold D, Dujovny N, Kalady M, Luchtefeld M, Whelan RL: Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels. Surg Endosc; 2009 Feb;23(2):409-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal resection, both open and laparoscopic-assisted, in patients with benign indications is associated with proangiogenic changes in plasma angiopoietin 1 and 2 levels.
  • INTRODUCTION: Plasma vascular endothelial growth factor (VEGF) levels are increased after surgery and may stimulate tumor growth after cancer resection.
  • This study's purpose was to determine the impact of open and minimally invasive (MIS) colorectal resection (CR) for benign indications on plasma Ang 1 and 2 levels.
  • CONCLUSION: CR for benign pathology results in higher Ang 2 levels, lower Ang 1 levels, and lower Ang 1 to Ang 2 ratios early after surgery.
  • These results, plus the already noted VEGF increases, suggest that surgery results in proangiogenic plasma protein changes that may stimulate tumor growth early after surgery.
  • [MeSH-major] Angiopoietin-1 / blood. Angiopoietin-2 / blood. Colectomy. Colonic Diseases / surgery. Laparoscopy. Rectal Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Surg Endosc. 2009 Feb;23(2):416. Kallady, M [corrected to Kalady, M]
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] J Pathol. 2004 Sep;204(1):1-10 [15307132.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):213-23 [10068209.001]
  • [Cites] Cardiovasc Res. 2001 Feb 16;49(3):659-70 [11166279.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):2-9 [10664112.001]
  • [Cites] World J Surg. 1996 May;20(4):460-4 [8662135.001]
  • [Cites] J Lab Clin Med. 2005 Apr;145(4):194-203 [15962838.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Science. 1998 Oct 16;282(5388):468-71 [9774272.001]
  • [Cites] Biochem Pharmacol. 2001 Feb 1;61(3):253-70 [11172729.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1670-4 [15540297.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):361-73 [11310829.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • (PMID = 18813991.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiopoietin-1; 0 / Angiopoietin-2
  •  go-up   go-down


51. Amato A: Colorectal gastrointestinal stromal tumor. Tech Coloproctol; 2010 Nov;14 Suppl 1:S91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000.
  • Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior.
  • Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors.
  • [MeSH-major] Colorectal Neoplasms. Gastrointestinal Stromal Tumors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):89-96 [17145623.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):981-2 [16583196.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1098-103 [15522557.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1091-5 [11021812.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):121-3 [16399120.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):585-93 [17646785.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] Surg Today. 2007;37(8):698-701 [17643218.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Scand J Surg. 2003;92(3):195-9 [14582540.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Colorectal Dis. 2008 Nov;10 (9):951-2 [18294266.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 20967481.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Ludlow A, Yee KO, Lipman R, Bronson R, Weinreb P, Huang X, Sheppard D, Lawler J: Characterization of integrin beta6 and thrombospondin-1 double-null mice. J Cell Mol Med; 2005 Apr-Jun;9(2):421-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the beta6-null and double-null mice displayed a significant elevation in benign and malignant cancers.
  • Stomach papillomas, squamous cell carcinomas of the ear and stomach, and adenocarcinomas of the lungs, vagina/cervix and colon were observed with the highest frequency.
  • They also indicate that alphavbeta6 functions as a tumor suppressor gene and that activation of TGFbeta by TSP-1 and alphavbeta6 contributes to normal tissue architecture and function.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963261.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86410; United States / NCI NIH HHS / CA / CA92644; United States / NHLBI NIH HHS / HL / HL53949; United States / NHLBI NIH HHS / HL / HL68003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Integrin beta Chains; 0 / Thrombospondin 1; 0 / Transforming Growth Factor beta; 0 / integrin beta6
  •  go-up   go-down


53. Bonin EA, Baron TH: Update on the indications and use of colonic stents. Curr Gastroenterol Rep; 2010 Oct;12(5):374-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the indications and use of colonic stents.
  • Self-expandable metal stent (SEMS) placement is a minimally invasive option for achieving acute colonic decompression in obstructed colorectal cancer.
  • Colorectal stenting offers nonoperative, immediate, and effective colon decompression and allows bowel preparation for an elective oncologic resection.
  • Colonic stent placement also offers effective palliation of malignant colonic obstruction, although it carries risks of delayed complications.
  • Despite concerns of tumor seeding following endoscopic colorectal stent placement, no difference exists in oncologic long-term survival between patients who undergo stent placement followed by elective resection and those undergoing emergency bowel resection.
  • Colorectal stents have also been used in selected patients with benign colonic strictures.
  • Patients with benign colonic stricture with acute colonic obstruction who are at high risk for emergency surgery can gain temporary relief of obstruction after SEMS placement; the stent can be removed en bloc with the colon specimen at surgery.
  • This article reviews the techniques and indications of SEMS placement for benign and malignant colorectal obstructions.
  • [MeSH-minor] Acute Disease. Colon / pathology. Colon / surgery. Colonic Diseases / etiology. Colonic Diseases / surgery. Constriction, Pathologic / surgery. Humans. Palliative Care. Pelvic Neoplasms / complications. Pelvic Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2009 Oct;19(5):e202-5 [19851253.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):178-83 [18477021.001]
  • [Cites] Lancet. 2006 Nov 4;368(9547):1573-4 [17084754.001]
  • [Cites] Scand J Surg. 2009;98(3):143-7 [19919918.001]
  • [Cites] J Gastrointest Surg. 2009 May;13(5):960-5 [19159986.001]
  • [Cites] South Med J. 2009 Dec;102(12):1257-9 [20016435.001]
  • [Cites] World J Surg. 2009 Jun;33(6):1281-6 [19363580.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):68-73 [18028916.001]
  • [Cites] J Am Coll Surg. 2001 Jun;192(6):719-25 [11400965.001]
  • [Cites] Brachytherapy. 2009 Jul-Sep;8(3):313-7 [19211311.001]
  • [Cites] Can J Gastroenterol. 2006 Dec;20(12):779-85 [17171197.001]
  • [Cites] Arch Surg. 2009 Dec;144(12):1127-32 [20026830.001]
  • [Cites] Surg Endosc. 2007 Feb;21(2):225-33 [17160651.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):799-805 [20363422.001]
  • [Cites] Gastrointest Endosc. 2010 Mar;71(3):560-72 [20189515.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):248-54 [19542421.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):24-30 [12544518.001]
  • [Cites] World J Gastroenterol. 2007 Aug 7;13(29):3977-80 [17663513.001]
  • [Cites] Curr Oncol Rep. 2009 Jul;11(4):293-7 [19508834.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jan;25(1):50-4 [19119510.001]
  • [Cites] Scand J Gastroenterol. 2010 Jun;45(6):725-31 [20205505.001]
  • [Cites] Colorectal Dis. 2009 May;11(4):405-9 [18513190.001]
  • [Cites] Radiology. 2010 Mar;254(3):774-82 [20177092.001]
  • [Cites] Dis Colon Rectum. 2009 Sep;52(9):1657-61 [19690497.001]
  • [Cites] Dis Colon Rectum. 2009 Jul;52(7):1272-7 [19571704.001]
  • [Cites] J Am Coll Surg. 2010 Jan;210(1):45-53 [20123331.001]
  • [Cites] BMC Surg. 2007 Jul 03;7:12 [17608947.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Am Surg. 2009 Oct;75(10):897-900 [19886130.001]
  • [Cites] Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):399-409 [19072388.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 May;21(5):585-6 [19282771.001]
  • [Cites] Dig Dis Sci. 2010 Jun;55(6):1732-7 [19693667.001]
  • [Cites] Surg Endosc. 2010 Mar;24(3):525-30 [19597776.001]
  • [Cites] Colorectal Dis. 2011 May;13(5):549-54 [20082633.001]
  • [Cites] Dis Colon Rectum. 2010 Feb;53(2):200-12 [20087096.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2007 Apr;17(2):323-39, vi [17556151.001]
  • [Cites] Gastrointest Endosc. 2009 Jun;69(7):1282-7 [19286179.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):675-80 [19251009.001]
  • [Cites] Surgery. 2008 Nov;144(5):786-92 [19081022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Nov;7(11):1174-6 [19631290.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1007-12 [18594837.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):454-62 [17704890.001]
  • (PMID = 20703837.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


54. Schäfer H, Baldus SE, Hölscher AH: Giant adenomas of the rectum: complete resection by transanal endoscopic microsurgery (TEM). Int J Colorectal Dis; 2006 Sep;21(6):533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal endoscopic microsurgery (TEM) offers an alternative operation method to low-anterior rectum resection in this potentially benign tumor situation.
  • A total of 33 patients met the criteria and were analyzed for postoperative complications, histology, and incidence of occult adenocarcinoma; residual tumor status; and tumor recurrence.
  • The residual adenoma status was 18% (n=6), especially in patients with tumors sizes more than 30 cm2.
  • In case of adenoma recurrence (n=4, 12%), a conventional transanal excision (Parks) was applicable, as these tumors were mostly located within the suture-line region of the lower rectum.
  • In case of advanced tumors (1xpT2, 1xpT3), anterior rectum resection was carried out, whereas for the early tumors (2xpT1 low risk, 1x1 pTis), no further therapy was added.
  • CONCLUSION: TEM is an alternative method for the resection of large benign rectal tumors located in the mid- and upper third of the rectum.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1987 Jan;153(1):41-7 [3799891.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1021-6 [15789125.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):255-9 [15273549.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):233-8 [7882783.001]
  • [Cites] Surg Endosc. 1995 Oct;9(10):1106-12 [8553213.001]
  • [Cites] Int J Colorectal Dis. 2003 Mar;18(2):131-5 [12548415.001]
  • [Cites] Proc R Soc Med. 1974 Jun;67(6 Pt 1):451-7 [4853754.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):86-9 [14702647.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Curr Top Pathol. 1990;81:277-93 [2407443.001]
  • [Cites] Am Surg. 1998 Dec;64(12):1170-3 [9843338.001]
  • [Cites] Br J Surg. 1973 Sep;60(9):688-95 [4582241.001]
  • [Cites] Am J Surg. 1997 May;173(5):383-5 [9168071.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):65-71 [3337563.001]
  • [Cites] Am J Surg. 1976 Feb;131(2):185-91 [175719.001]
  • [Cites] Am J Surg. 1975 Dec;130(6):729-32 [1200290.001]
  • [Cites] Chirurg. 2005 Apr;76(4):379-84 [15502890.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):183-8 [8857131.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Surg Clin North Am. 1997 Feb;77(1):229-39 [9092112.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 16133003.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. John R, El-Rouby NM, Tomasetto C, Rio MC, Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol; 2007 07;22(7):743-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TFF3 during multistep colon carcinogenesis.
  • The pathogenesis of colon cancer is not well understood.
  • This common type of cancer is generally believed to occur in a multistep process which involves alterations of various tumor suppressor genes and oncogenes during the progression through benign lesions towards carcinoma.
  • TFF3 is a product of the colonic epithelium and has been implicated in colonic mucosal protection and also in the aggressiveness of colon cancer cells.
  • The aim of this study was to analyze the expression of TFF3 during propagation towards cancer development in the human colon.
  • Colonic tissues representing colitis, adenomatous polyposis, tubulovillous adenoma, and mucoid/adeno-carcinomas were processed for immunohistochemistry using an antibody specific for human TFF3.
  • The results were correlated with those of PCNA-labeling, quantified, and compared with those of control tissues obtained from the safe margin of macroscopically normal colonic mucosa of patients with colon cancer.
  • Colonic tissues with highly invasive cancer cells were characterized by statistically significant down-regulation of TFF3 expression.
  • The changes observed in expression of TFF3 showed an inverse correlation with cell proliferation and suggest that it might play a protective role against colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Adenoma, Villous / chemistry. Adenomatous Polyposis Coli / chemistry. Colitis / metabolism. Colonic Neoplasms / chemistry. Peptides / analysis
  • [MeSH-minor] Adult. Cell Proliferation. Cell Transformation, Neoplastic / chemistry. Colon / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Trefoil Factor-3

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455148.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Peptides; 0 / Proliferating Cell Nuclear Antigen; 0 / TFF3 protein, human; 0 / Trefoil Factor-3
  •  go-up   go-down


56. Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM: A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. Hybridoma (Larchmt); 2007 Feb;26(1):22-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunostaining of MMP-7 in normal tissues or benign tumors of intestinal, breast, and prostatic origin indicates that this protein is normally localized luminally in glandular epithelium.
  • The localization pattern would suggest that in normal or early stage tumors, MMP-7 is most likely not directly involved in extracellular matrix degradation.
  • In contrast, advanced colon tumors show MMP-7 in invading cells at the advancing edge of the tumor.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 2002 Dec;70(9-10):561-73 [12492497.001]
  • [Cites] Curr Biol. 1999 Dec 16-30;9(24):1441-7 [10607586.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Science. 1999 Oct 1;286(5437):113-7 [10506557.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Prostate. 1996 Sep;29(3):159-68 [8827084.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Feb;28(2):123-36 [8729000.001]
  • [Cites] Protein Expr Purif. 1994 Feb;5(1):27-36 [8167471.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1423-47 [15131803.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):119-35 [15000153.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1831-43 [12759241.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Clin Invest. 2000 Jan;105(2):143-50 [10642592.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • (PMID = 17316082.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA60867; United States / NCI NIH HHS / CA / R01 CA84360; United States / NIAMS NIH HHS / AR / AR36457; United States / NCI NIH HHS / CA / R01 CA084360; United States / NIAMS NIH HHS / AR / P30 AR48311; United States / NIAMS NIH HHS / AR / P30 AR048311; United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enzyme Precursors; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ NIHMS403810; NLM/ PMC3838102
  •  go-up   go-down


57. Modlin IM, Shapiro MD, Kidd M: An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg; 2005 Jan;29(1):92-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of rare carcinoid tumors: clarifying these clinical conundrums.
  • Carcinoid tumors are distinct neuroendocrine neoplasms with characteristic histological, clinical, and biological properties.
  • Though commonly associated with the gastrointestinal tract and bronchopulmonary system, a substantial number of these tumors originate in less common anatomical sites and can range from indolent, unrecognized entities to highly active, metastatic secretory tumors.
  • The authors reviewed 13,715 carcinoid tumors identified by three consecutive registries of the National Cancer Institute (NCI) from 1950 to 1999, focusing on the anatomic sites accounting for less than one percent of all carcinoids.
  • In addition, data from the world's literature published on carcinoid tumors within these particular anatomic locations were then analyzed with respect to incidence, clinical presentation, symptoms, diagnostic evaluation, microscopic and immunohistochemical findings, treatment strategies, and prognosis.
  • The primary organs in which carcinoids are most commonly mistaken for some of the more conspicuous endemic tumors include the esophagus, pancreas, liver, biliary tract, gallbladder, and Meckel's diverticulum, as well as within the pelvic and otolaryngeal organs and the breast.
  • Tumors with the worst prognosis were those that involved the pancreas (37.5%: 5-year survival) and those in the cervix (12-33%: 3-year survival).
  • The diminution of the likelihood of inadvertently neglecting these often benign, indolent neoplasms that are well known to metastasize if unaddressed would represent an important advance.
  • Familiarity with such unusual sites of origin will facilitate appropriate recognition and characterization of such tumors, allowing for timely intervention.
  • [MeSH-major] Carcinoid Tumor / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):153-8 [8604242.001]
  • [Cites] Ultrastruct Pathol. 1993 Jan-Feb;17(1):115-21 [8427027.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):229-35 [7546678.001]
  • [Cites] Cancer. 1984 Oct 15;54(8):1705-13 [6383596.001]
  • [Cites] Patol Pol. 1978 Apr-Jun;29(2):237-40 [704186.001]
  • [Cites] N Y State J Med. 1969 May 15;69(10):1337-9 [5255420.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1334-9 [11688471.001]
  • [Cites] Lancet. 1954 Nov 6;267(6845):951 [13213086.001]
  • [Cites] Z Gastroenterol. 1974 Sep;12 Suppl(0):377-84 [4418379.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):897-909 [1707237.001]
  • [Cites] Intern Med. 1996 Dec;35(12 ):953-6 [9030993.001]
  • [Cites] J Urol. 1977 Nov;118(5):777-82 [916100.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2189-95 [10521965.001]
  • [Cites] J Gastroenterol. 1995 Jun;30(3):398-402 [7647908.001]
  • [Cites] Cancer. 1975 Aug;36(2):404-18 [1157010.001]
  • [Cites] Digestion. 1997;58(4):410-4 [9324172.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):187-211 [8173736.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Ital J Surg Sci. 1986;16(4):249-53 [3557930.001]
  • [Cites] Gynecol Oncol. 1996 May;61(2):259-65 [8626144.001]
  • [Cites] Thorax. 1989 Jul;44(7):594-6 [2672408.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1476-81 [9118026.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1726-32 [7688660.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):93-5 [7679854.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1109-16 [8758239.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4209-13 [10566674.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):281-3 [7789401.001]
  • [Cites] Pathol Annu. 1979;14 Pt 1:273-91 [42037.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):217-20 [2776604.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):281-8 [7673859.001]
  • [Cites] Z Gastroenterol. 1998 Mar;36(3):233-8 [9577907.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):141-8 [10713946.001]
  • [Cites] J Urol. 1954 Nov;72(5):892-4 [13212896.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Int J Urol. 2001 Sep;8(9):522-4 [11683977.001]
  • [Cites] Histopathology. 1987 Jan;11(1):53-62 [2881873.001]
  • [Cites] J Am Osteopath Assoc. 2000 Jul;100(7):432-4 [10943090.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1462-7 [9840084.001]
  • [Cites] Surgery. 1998 Nov;124(5):831-8 [9823395.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):547-52 [2164339.001]
  • [Cites] J Laryngol Otol. 1983 Nov;97(11):1073-80 [6644166.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Acta Oncol. 1993;32(2):225-9 [7686765.001]
  • [Cites] Heart. 1998 Dec;80(6):623-6 [10065036.001]
  • [Cites] Jpn J Clin Oncol. 1989 Dec;19(4):397-401 [2607641.001]
  • [Cites] Cancer. 1975 Aug;36(2):560-9 [1157019.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1959-65 [10570419.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1501-10 [11075851.001]
  • [Cites] Ear Nose Throat J. 2002 Jan;81(1):40-3 [11816388.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Ann R Coll Surg Engl. 1959 Dec;25(5):277-97 [19310224.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] Arch Otolaryngol. 1969 Jul;90(1):64-7 [5785991.001]
  • [Cites] Can J Surg. 1999 Feb;42(1):59-63 [10071590.001]
  • [Cites] Acta Cytol. 1990 Mar-Apr;34(2):119-24 [2181800.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):261-4 [9607629.001]
  • [Cites] Diagn Cytopathol. 2001 Sep;25(3):168-71 [11536440.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:159-69 [12381551.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):589-96 [1587179.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):609-12 [8631405.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):23-32 [14687136.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Arch Anat Pathol (Paris). 1964 Sep;12:200-3 [14228034.001]
  • [Cites] Am J Clin Pathol. 1980 Jun;73(6):816-23 [6156597.001]
  • (PMID = 15599742.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


58. Littrup PJ, Ahmed A, Aoun HD, Noujaim DL, Harb T, Nakat S, Abdallah K, Adam BA, Venkatramanamoorthy R, Sakr W, Pontes JE, Heilbrun LK: CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol; 2007 Mar;18(3):383-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These 49 masses included 36 primary renal cell carcinomas (RCCs), 3 oncocytomas, 1 angiomyolipoma, 6 renal inflammatory lesions, 2 benign parenchymal changes, and 1 colon cancer metastasis.
  • All cryotherapy zones were well defined by CT during ablation as hypodense ice with an average diameter of 5.3 cm, covering an average tumor size of 3.3 cm.
  • Average ablation zone diameters showed significant reduction over time (P < .001), becoming significantly less than the original tumor size by 12 months (P < .05).
  • CONCLUSIONS: Percutaneous renal cryotherapy is a well-tolerated outpatient procedure that allows safe, CT monitoring of ice formation beyond visible tumor margins.
  • With appropriate cryoprobe placements, a low failure rate appears less dependent on tumor size or location.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377184.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


59. Shantha Kumara HM, Cabot JC, Hoffman A, Luchtefeld M, Kalady MF, Hyman N, Feingold D, Baxter R, Whelan RL: Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period. Surg Endosc; 2009 Apr;23(4):694-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period.
  • VEGF induces wound and tumor angiogenesis by binding to endothelial cell (EC)-bound VEGF-receptor 1 (VEGFR1) and VEGFR2.
  • The importance of the MICR-related VEGF changes depends on the effect of surgical procedures on sVEGFR1 and sVEGFR2; this study assessed levels of these proteins after MICR for benign indications.
  • [MeSH-major] Colectomy / methods. Colonic Diseases / surgery. Minimally Invasive Surgical Procedures / methods. Vascular Endothelial Growth Factor Receptor-1 / blood. Vascular Endothelial Growth Factor Receptor-2 / blood

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Feb;22(2):287-97 [18204877.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):44-50 [7615975.001]
  • [Cites] Clin Chem Lab Med. 1998 Jun;36(6):379-83 [9711425.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):295-301 [18782657.001]
  • [Cites] J Vasc Surg. 1998 Sep;28(3):535-40 [9737465.001]
  • [Cites] Am J Cardiol. 1999 Feb 1;83(3):337-9 [10072219.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):405-10 [17214745.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):490-8 [10667605.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Sci STKE. 2001 Dec 11;2001(112):re21 [11741095.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):608-13 [16891801.001]
  • [Cites] Crit Care Med. 2008 Apr;36(4):1284-9 [18379256.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):617-23 [11274009.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3824-30 [10339489.001]
  • [Cites] Shock. 2008 Apr;29(4):452-7 [18598002.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):792-8 [17060773.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Circ Res. 2001 Feb 2;88(2):167-74 [11157668.001]
  • [Cites] Clin Sci (Lond). 1997 May;92(5):453-4 [9176017.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):409-15 [18813991.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1931-4 [11929804.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):331-5 [12653578.001]
  • [Cites] Eur Respir J. 2001 Jul;18(1):100-6 [11510779.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Cancer. 2004 May 1;100(9):1884-91 [15112269.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):182-8 [10606981.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1375-9 [1402682.001]
  • (PMID = 19184203.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


60. Wang XP, Li ZJ, Magnusson J, Brunicardi FC: Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers. World J Surg; 2005 Mar;29(3):334-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In previous studies, we demonstrated that rat insulin promoter (RIP)-driven gene therapy successfully targeted human pancreatic tumor PANC-1 cells and mouse insulinoma NIT-1 cells, which are both pancreatic duodenal homeobox-1 (PDX-1)-positive.
  • The custom-designed Tissue MicroArray of human tumor specimens consists of human cancer specimens from different origins, such as the pancreas, breast, colon, prostate, kidney, liver, lung, and ovary.
  • PDX-1 expression intensity was elevated in both benign and malignant tissues from the same patient with pancreas, breast, colon, prostate, and kidney cancers, whereas normal human tissues from control subjects without cancer did not express PDX-1.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):98-108; discussion 106-8 [14746841.001]
  • [Cites] Surgery. 2003 Aug;134(2):260-6 [12947327.001]
  • [Cites] Surgery. 2000 Aug;128(2):353-60 [10923016.001]
  • [Cites] Cancer Gene Ther. 2001 Nov;8(11):869-78 [11773977.001]
  • [Cites] Gene Ther. 2001 Feb;8(3):199-208 [11313791.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1763-8 [9637677.001]
  • [Cites] Gene Ther. 2000 Mar;7(6):518-26 [10757026.001]
  • [Cites] Pancreas. 2004 Mar;28(2):109-20 [15028942.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Ann Surg. 2001 May;233(5):603-11 [11323498.001]
  • [Cites] Development. 1996 May;122(5):1409-16 [8625829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jul;78(7):4458-60 [7027261.001]
  • [Cites] Diabetes. 2003 Jul;52(7):1732-7 [12829640.001]
  • [Cites] J Mol Med (Berl). 1997 May;75(5):327-40 [9181474.001]
  • [Cites] Development. 1989 Apr;105(4):787-94 [2574662.001]
  • [Cites] Diabetes. 2001 Feb;50 Suppl 1:S131-2 [11272171.001]
  • [Cites] Aust N Z J Surg. 1998 Feb;68(2):90-100 [9493997.001]
  • [Cites] World J Surg. 2004 Aug;28(8):826-33 [15457366.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):106-10 [8988180.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4827-36 [11406559.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4251-9 [7901001.001]
  • [Cites] Gut. 2004 Mar;53(3):323-30 [14960508.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25279-86 [11309388.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1416-26 [10579983.001]
  • [Cites] Development. 1995 Jan;121(1):11-8 [7867492.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1688-94 [11527697.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9180-5 [10900262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10332-7 [11526239.001]
  • [Cites] EMBO J. 1994 Mar 1;13(5):1145-56 [7907546.001]
  • [Cites] Nature. 1994 Oct 13;371(6498):606-9 [7935793.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:1-4 [10415845.001]
  • [Cites] Semin Gastrointest Dis. 2000 Jul;11(3):162-7 [10950464.001]
  • (PMID = 15706433.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA95731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


61. Cui Y, Koop EA, van Diest PJ, Kandel RA, Rohan TE: Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer. Breast Cancer Res Treat; 2007 Jul;104(1):103-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometric features in benign breast tissue and risk of subsequent breast cancer.
  • Certain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients.
  • We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.
  • The study was nested within a cohort of 4,888 women with a histopathologic diagnosis of benign breast disease (BBD) and involved 61 cases and 71 controls, amongst whom there were 53 matched case-control sets.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2002 Oct 15;59(2):109-18 [12373721.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):282-5 [11494225.001]
  • [Cites] Histopathology. 2004 Oct;45(4):352-9 [15469473.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):9-18 [7123847.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):603-9 [3722413.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):270-5 [2381167.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):11-23 [2562217.001]
  • [Cites] Eur J Surg Oncol. 1991 Aug;17(4):350-3 [1874292.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1459-76 [1423087.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):374-82 [8908309.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9 [9731732.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):800-5 [9743304.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Urology. 1999 Jan;53(1):44-9 [9886586.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):386-92 [10223762.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(5):257-61 [10392302.001]
  • [Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):768-72 [15824141.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):297-9 [16034016.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3542-8 [10589770.001]
  • [Cites] Pathol Res Pract. 1999;195(11):741-6 [10605693.001]
  • [Cites] Pol J Pathol. 1999;50(4):235-41 [10721263.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):494-9 [11102893.001]
  • [Cites] J Pathol. 2001 Jan;193(1):33-9 [11169513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59 [11303595.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):836-41 [12766590.001]
  • (PMID = 17061043.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2092407
  •  go-up   go-down


62. Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, Piao YS, Yoshimoto T, Minamoto T, Kotani H, Taketo MM, Oshima M: Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology; 2009 Oct;137(4):1346-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The activation of Wnt/beta-catenin signaling causes the development of gastric and colon cancers.
  • Sox17 represses Wnt/beta-catenin signaling and is down-regulated in colon cancer.
  • METHODS: Sox17 expression was examined in gastrointestinal tumors of mouse models and humans.
  • RESULTS: Sox17 was induced in K19-Wnt1/C2mE mouse gastric tumors and K19-Wnt1 preneoplastic lesions, where Wnt/beta-catenin signaling was activated.
  • In contrast, Sox17 was rarely detected by immunohistochemistry in gastric and colon cancers, whereas strong nuclear staining of Sox17 was found in >70% of benign gastric and intestinal tumors.
  • Finally, transgenic expression of Sox17 suppressed dysplastic tumor development in K19-Wnt1/C2mE mouse stomach.
  • CONCLUSIONS: Sox17 plays a tumor suppressor role through suppression of Wnt signaling.
  • It is therefore conceivable that Sox17 protects benign tumors from malignant progression at an early stage of tumorigenesis, and down-regulation of Sox17 contributes to malignant progression through promotion of Wnt activity.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Cyclooxygenase 2 / genetics. DNA Methylation. Down-Regulation. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genotype. Humans. Intramolecular Oxidoreductases / genetics. Keratin-19 / genetics. Mice. Mice, Inbred C57BL. Mice, Transgenic. Phenotype. Promoter Regions, Genetic. Time Factors. Transfection. Tumor Cells, Cultured. Up-Regulation. Wnt1 Protein / genetics. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549530.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGB Proteins; 0 / Keratin-19; 0 / SOX17 protein, human; 0 / SOXF Transcription Factors; 0 / Sox17 protein, mouse; 0 / Wnt1 Protein; 0 / beta Catenin; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase
  •  go-up   go-down


63. Thorat MA, Morimiya A, Mehrotra S, Konger R, Badve SS: Prostanoid receptor EP1 expression in breast cancer. Mod Pathol; 2008 Jan;21(1):15-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EP1 has also been shown to decrease the incidence of colon cancer in mouse models.
  • Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses.
  • The data were compared with and correlated with other prognostic factors like tumour size, tumour grade, lymph node status, oestrogen receptor, progesterone receptor (PR), HER2/neu and cyclooxygenase-2.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Receptors, Prostaglandin E / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Nucleus / chemistry. Cyclooxygenase 2 / analysis. Cytoplasm / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Receptors, Prostaglandin E, EP1 Subtype. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906615.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37403; United States / NIAMS NIH HHS / AR / K08 AR
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PTGER1 protein, human; 0 / Ptger1 protein, mouse; 0 / Ptger1 protein, rat; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP1 Subtype; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


64. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • Furthermore, MR colography evaluating the rest of the colon past the stenosis was possible with all patients.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • Furthermore, the potential is big in performing a full preoperative colon evaluation even in patients with obstructing cancer.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


66. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


67. Colović R, Grubor N, Radak V, Micev M, Stojković M, Colović N: [Aggressive intraabdominal fibromatosis]. Vojnosanit Pregl; 2006 Sep;63(9):839-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraabdominal or mesenteric fibromatosis is a rare benign nonmetastatic neoplasm that appears as a sporadic lesion or in patients with familiar polyposis.
  • CASE REPORT: We presented a 22-year-old woman in whom an aggressive intraabdominal fibromatosis had appeared during the first pregnancy as a well circumscribed ovoid tumor, involving the terminal ileum, the caecum, the ascending colon, the right kidney, the ureter, and the right common iliac artery.
  • The tumor was excised with right colectomy, nephroureterectomy and resection of the involved artery using arterial reconstruction with graft interposition.
  • Two years after the surgery the patient developed an inoperable tumor recurrency with a fatal outcome.
  • CONCLUSION: In spite of a successful surgical excision during the original surgery intraabdominal or mesenteric fibromatosis might have an aggressive evolution leading to an inoperable tumor recurrency and a fatal outcome.
  • [MeSH-major] Fibromatosis, Abdominal / pathology. Fibromatosis, Aggressive / pathology. Neoplasm Recurrence, Local. Pregnancy Complications, Neoplastic / pathology


68. Gravante G, Delogu D, Venditti D: Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a left colon adenocarcinoma anastomotic recurrence that metastasized to a benign transsphincteric fistula-in-ano, presumably through the implantation of viable malignant cells shed from the secondary tumor, and discuss the implications of these findings in colorectal cancer surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716545.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


69. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


70. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J: Tumor microenvironment and progression of pancreatic cancer. Exp Oncol; 2010 Sep;32(3):128-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor microenvironment and progression of pancreatic cancer.
  • Pancreatic ductal adenocarcinoma is characterized by « tumor desmoplasia », a remarkable increase in connective tissue that penetrates and envelopes the neoplasm.
  • It is becoming clear that this desmoplastic microenvironment of pancreatic cancer--which is forming approximately eighty percent of the tumor mass--is not a passive scaffold for the tumor cells but an active player in carcinogenesis.
  • Several chemotherapeutic agents and novel molecular targeted therapies against epithelial tumor cells--although showing antitumor activity in cell culture and mouse experiments--have failed to show significant effects in the clinic.
  • Thus, targeting pancreatic tumor cells alone seems unlikely to improve the dismal prognosis of pancreatic cancer.
  • Several primarily benign conditions associated with expansion of stromal and inflammatory components, such as chronic pancreatitis or hereditary pancreatitis are believed to increase the risk of pancreatic cancer.
  • Similar observations have been made in other cancer types such as chronic hepatitis-liver cancer, Barrett dyplasia-esophageal cancer, and inflammatory bowel disease-colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Pancreas / pathology. Pancreatic Neoplasms / metabolism. Tumor Microenvironment

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21403605.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ukraine
  •  go-up   go-down


71. Moussi A, Nouira R, Bourguiba B, Daldoul S, Zaouche A: A rare cause of lower gastrointestinal bleeding. Tunis Med; 2010 Dec;88(12):961-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyoma of the colon are rare benign smooth muscle tumours.
  • The colonoscopy showed an active bleeding from the right colon but it was enable to specify the nature and the exact seat of the bleeding lesion.
  • An emergent operation showed a tumor of the right colic angle of 8 cm.
  • CONCLUSION: Colic leiomyomas are rare benign tumours.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Gastrointestinal Hemorrhage / etiology. Leiomyoma / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21136371.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


72. Egberts JH, Schafmayer C, Bauerschlag DO, Jänig U, Tepel J: Benign abdominal and pulmonary metastasizing leiomyoma of the uterus. Arch Gynecol Obstet; 2006 Aug;274(5):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign abdominal and pulmonary metastasizing leiomyoma of the uterus.
  • BACKGROUND: Benign metastasizing leiomyoma (BML) is a rare disease in which the lung is described to be the most afflicted extrauterine organ.
  • She was admitted to our hospital for investigation of a huge tumor mass in the pelvis consisting of multiple nodules in the abdomen and left lung.
  • Assuming an advanced intraperitoneal malignancy was present, a 'palliative' limited tumor debulking and due to a tumor compressing the sigmoid a Hartmann's procedure was performed.
  • In the presence of a stable disease after 12 months, the patient underwent a re-laparotomy with a reanastomosis of the colon.
  • CONCLUSIONS: The review of the literature supports the concept that the primary tumor of BML is located in the uterus and that leiomyomas in the uterus can metastasize leading via hematogenous spread to BML.
  • However, the origin of the tumor remains controversial.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649038.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Okubo H, Ozeki K, Tanaka T, Matsuo T, Mochinaga N: Primary malignant fibrous histiocytoma of the ascending colon: report of a case. Surg Today; 2005;35(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the ascending colon: report of a case.
  • We report a rare case of primary malignant fibrous histiocytoma (MFH) of the ascending colon.
  • A 66-year-old man presented to our hospital with epigastralgia, and abdominal ultrasonography and computed tomography showed a large soft-tissue mass in the ascending colon.
  • Barium enema and endoscopic examination showed a huge tumor in the ascending colon.
  • At laparotomy, we found a tumor in the ascending colon and performed a right hemicolectomy with en bloc lymph node dissection.
  • The resected specimen contained a tumor measuring 14.5 x 8.0 x 4.5 cm, the cut surface of which was yellowish.
  • Based on histological and immunohistological studies, the tumor was diagnosed as MFH of the ascending colon.
  • [MeSH-major] Colon, Ascending. Colonic Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815852.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


74. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic tumors in the eyes of urologists].
  • [Transliterated title] Raumforderungen im kleinen Becken aus Sicht des Urologen.
  • Pelvic tumors originating from outside the urinary tract commonly invade the urogenital organs by direct extension mainly because of the close relationships between the pelvic organs.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • This is also the case with malignant tumors of the uterus, ovaries, cervix and colon where infiltration of the urogenital organs might be noted.
  • These are the symptoms that lead to the diagnosis of the primary tumor.
  • It has to be kept in mind that urogenital tumors with such symptoms have to be included in the differential diagnosis.
  • The possibility of eradicating the tumor is then to be discussed after relieving the obstruction.
  • [MeSH-minor] Cystectomy. Cystoscopy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prostatectomy. Quality of Life. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


75. Soslow RA, Ali A, Oliva E: Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol; 2008 Jul;32(7):1013-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the epithelial component is typically benign, the mesenchymal component of most adenosarcomas morphologically resembles that observed in endometrial stromal tumors and is responsible for their clinical behavior.
  • Thus, the differential diagnosis usually includes not only low-grade endometrial stromal tumors, but also adenofibroma, carcinosarcoma, and embryonal rhabdomyosarcoma especially in small samples.
  • Thirty tumors arose in the uterus, 4 were pelvic, and 1 originated in the colon.
  • CD34 expression was found in 35% of the tumors, but it was almost always patchy in distribution and weak in intensity, as was calretinin expression, seen only in 12% of the cases.
  • Expression of c-kit and inhibin in greater than 5% of the tumor cells was not encountered.
  • In summary, the immunophenotype of most MAs resembled that of endometrial stromal tumors (positive for ER, PR, WT1, and CD10, with variable expression of muscle markers, AR and cytokeratin).
  • [MeSH-major] Adenosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / diagnosis. Biomarkers, Tumor / analysis. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Rhabdomyosarcoma, Embryonal / diagnosis. Sarcoma, Endometrial Stromal / diagnosis. Stromal Cells / metabolism. Stromal Cells / pathology